Clinical and Molecular Hepatology

"Antiviral agent"

Reply to Correspondence

Reply to correspondence on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Heejoon Jang, Won Kim; Clin Mol Hepatol 2026;32(2):e254-e256.
Published online June 9, 2025; DOI: https://doi.org/10.3350/cmh.2025.0533

2,757 View
30 Download

Correspondences

Correspondence to editorial 1 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Rui Huang, Mindie H. Nguyen; Clin Mol Hepatol 2026;32(1):e83-e84.
Published online May 8, 2025; DOI: https://doi.org/10.3350/cmh.2025.0479

Citations

Citations to this article as recorded by

Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B”
Shang-Chin Huang, Jia-Horng Kao
Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef

3,595 View
15 Download
Crossref

Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Rui Huang, Mindie H. Nguyen; Clin Mol Hepatol 2026;32(1):e85-e86.
Published online May 8, 2025; DOI: https://doi.org/10.3350/cmh.2025.0478

Citations

Citations to this article as recorded by

Reply to correspondence on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Heejoon Jang, Won Kim
Clinical and Molecular Hepatology.2026; 32(2): e254. CrossRef

2,807 View
18 Download
Crossref

Editorial

Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”: Heejoon Jang, Won Kim; Clin Mol Hepatol 2026;32(1):426-428.
Published online April 28, 2025; DOI: https://doi.org/10.3350/cmh.2025.0430

Citations

Citations to this article as recorded by

Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
Rui Huang, Mindie H. Nguyen
Clinical and Molecular Hepatology.2026; 32(1): e85. CrossRef

3,572 View
56 Download
1 Web of Science
Crossref

Correspondence

Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients: Correspondence to letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”: Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu; Clin Mol Hepatol 2026;32(1):e99-e102.
Published online April 4, 2025; DOI: https://doi.org/10.3350/cmh.2025.0362

5,269 View
37 Download
1 Web of Science

Reviews

Viral hepatitis

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0: Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Meifang Han, Weiming Yan, Hong Ren, Peng Hu, Sainan Shu, Paul Yien Kwo, Fu-sheng Wang, Man-Fung Yuen, Qin Ning; Clin Mol Hepatol 2025;31(Suppl):S134-S164.
Published online January 22, 2025; DOI: https://doi.org/10.3350/cmh.2024.0780

Abstract
PDF

As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.

Citations

Citations to this article as recorded by

Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Dynamics and Sensitivity of the Lifecycle of Hepatitis B Virus
Dmitry Grebennikov, Igor Sazonov, Rostislav Savinkov, Matvey Zakharov, Mark Sorokin, Yakov Mokin, Andreas Meyerhans, Gennady Bocharov
Pathogens.2026; 15(2): 172. CrossRef
ZNF638 represses the transcription of HBV closed circular DNA involving HUSH complex-mediated histone modifications of epigenetic silencing
Sifan Meng, Jiaqian Li, Yunlong Fang, Binwei Duan, Jing Wang, Yang Si, Feng Li, Qiong Wu, Shan Cheng, Wei Ding
Cell Communication and Signaling.2026;[Epub] CrossRef
Response to letters to editor "Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial" and “Critical Appraisal of the Anchor RCT on Entecavir, Peginterferon Alfa-2b, and GM-CSF Combination Therapy”
Di Wu, Da Huang, Weiming Yan, Qin Ning
Hepatology International.2026;[Epub] CrossRef
Response to letter to editor—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon
Jianxia Dong, Sujun Zheng, Xinyue Chen
Hepatology International.2026;[Epub] CrossRef
Mechanisms and management of pegylated interferon-α toxicity in chronic hepatitis B
Liya Zhu, Fei Peng, Dingfang Pi, Jinzhi Lu
Frontiers in Immunology.2026;[Epub] CrossRef
Long-term antiviral therapy sustains HBsAg decline, increases HBV RNA negativity and enhances the proportion of patients achieving functional cure in chronic hepatitis B
Ruihan Gao, Shuting Liu, Shiyu Zhang, Xin Zhou, Bin Zhu, Baoju Wang
Annals of Hepatology.2026; 31(2): 102212. CrossRef
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks
Kui Wang, Ruchen Zhou
Clinical and Molecular Hepatology.2026; 32(2): e211. CrossRef
A Comparative Study of Entecavir and Tenofovir Alafenamide on Quantitative HBsAg Reduction in Patients With CHB
Jungnam Lee, Young‐Joo Jin
Journal of Medical Virology.2026;[Epub] CrossRef
Hepatitis B in Children: A Review of Current Knowledge and Future Directions
Paola Carolina Espin Diaz, Swati Antala
Current Treatment Options in Pediatrics.2026;[Epub] CrossRef
Functional cure for chronic hepatitis B on hepatocellular carcinoma prevention: Evidence and clinical implications
Wen Kang, Yu-Shen Liu, Tian-Ping Wang, Shu-Ming Zhang, Yu Li, Ye Zhang
iLIVER.2026; 5(2): 100235. CrossRef
Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controll
Qiran Zhang, Feng Sun, Shulan Sui, Jianmei Lin, Chuncheng Wu, Jing Yuan, Yingli He, Jia Shang, Tao Han, Ying Zhu, Zuxiong Huang, Chen Chen, Chao Qiu, Xing Wang, Jiming Zhang, Yao Xie, Wenhong Zhang
Advances in Therapy.2026;[Epub] CrossRef
Residual viral expression in siRNA-treated HBV-replicating cell and mouse models
Mingzhu Xu, Yuyan Qian, Ziyang Song, Haiyu Wang, Lei Yue, Jiangxia Liu, Yaming Li, Wenjing Zai, Zhenghong Yuan, Jieliang Chen
Antiviral Research.2025; 240: 106210. CrossRef
Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection
Yiwen Shu, Sumeng Li, Yanqin Du, Xin Zheng
Frontiers in Immunology.2025;[Epub] CrossRef
Quantitatively Evaluate the Improvement of Functional Cure for the Quality of Life of Chronic Hepatitis B Cases: Evidence from a Cross-Sectional Study in China
Sihui Zhang, Zhiliang Gao, Hui Li, Yi Kang, Lei Fu, Xuebing Chen, Xiaoyuan Xu, Xinyue Chen, Hui Zhuang, Hui Zheng, Fuqiang Cui
Healthcare.2025; 13(20): 2590. CrossRef
Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study
Yong-Hong Wang, Ya-Chao Tao, Meng-Lan Wang, Cheng-Run Song, Jiang-Nan Peng, En-Qiang Chen
Journal of Virus Eradication.2025; 11(4): 100617. CrossRef
An RNA interference therapeutic potentially achieves functional cure of chronic hepatitis B virus infection
Ze-Ao Huang, Yang Yang, Shuo Yang, Guang-Shen Ji, Rui Fu, Zhi-Kang Tian, Yu-Cheng Wu, Geng-Shen Song
Nature Communications.2025;[Epub] CrossRef
A Study on Serum Protein Tracking in Patients with Low Levels of HBsAg Undergoing Treatment for Chronic Hepatitis B with a Combination of Tenofovir Disoproxil Fumarate and Pegylated Interferon
Yimin Chen, Min Deng, Mingkai Tong, Peixia Lin, Hua Xuan, Dahai Wei
Hepatitis Monthly.2025;[Epub] CrossRef
Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study
Jianxia Dong, Shan Ren, Jing Zhao, Pengxuan Wu, Haitian Yu, Yao Xie, Junliang Fu, Xiaorong Mao, Zhiliang Gao, Bingliang Lin, Qingfa Ruan, Yongfang Jiang, Xiulan Xue, Yueyong Zhu, Haidong Zhao, Haifang Cao, Xinyue Chen, Sujun Zheng
Virology Journal.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens
Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao
Hepatoma Research.2025;[Epub] CrossRef

19,092 View
674 Download
20 Web of Science
Crossref

Viral hepatitis

Prospect of emerging treatments for hepatitis B virus functional cure: Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen; Clin Mol Hepatol 2025;31(Suppl):S165-181.
Published online November 14, 2024; DOI: https://doi.org/10.3350/cmh.2024.0855

Abstract
PDF

Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is a favorable treatment endpoint in chronic hepatitis B (CHB). Nonetheless, functional cure is rarely attained with the current treatment modalities of nucleos(t)ide analogues (NUCs) and pegylated interferon alpha. Multiple novel virus-targeting agents and immunomodulators are under development for HBV with functional cure as the treatment goal. Among virus-targeting agents, antisense oligonucleotides and small-interfering RNAs are the most advanced in the developmental pipeline, and can induce potent and sustainable HBsAg suppression. The other virus-targeting agents have varying effects on HBsAg and HBV DNA, depending on the drug mechanism. In contrast, immunomodulators have modest effects on HBsAg and have limited roles in monotherapy. Multiple combination regimens incorporating RNA interference agents with immunomodulators have been studied through many ongoing clinical trials. These combination strategies demonstrate synergistic effects in inducing functional cure, and will likely be the future direction of development. Despite the promising results, research is warranted to optimize treatment protocols and to establish criteria for NUC withdrawal after novel therapies. Functional cure is now an attainable target in CHB, and the emerging novel therapeutics will revolutionize CHB management.

Citations

Citations to this article as recorded by

Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure
Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen
Gut.2026; 75(1): 119. CrossRef
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalentl
Mehrangiz Dezhbord, Kyun-Hwan Kim
Clinical and Molecular Hepatology.2026; 32(1): 385. CrossRef
Targeting the innate immune system in treating hepatitis B: prospects for functional cure
Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Clinical and Molecular Hepatology.2026; 32(1): 184. CrossRef
Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients
Yandan Wu, Yu Zhao, Ruixue Ji, Pinqing Li, Huijuan Chen, Fangping Yue, Yi Wu, Jie Qiu, Chuanlai Shen
Frontiers in Immunology.2026;[Epub] CrossRef
Group-based trajectory modeling for declines in hepatitis B surface antigen over time accurately identifies chronic hepatitis B patients achieving functional cure: a single-center cohort study in China
Yuchen Peng, Liping Liu, Xiaoping Wu
Annals of Medicine.2026;[Epub] CrossRef
Risk Prediction of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance in Patients With Chronic Hepatitis B
Shuaibing Ying, Jinyao Dai, Qiudan Zhang, Yujing Wang, Yina Yu, Zhijuan Zhang, Shaohua Dong, Yichun Zhang, Haoyang Hu, Yuqi Hong, Yi Liu, Yuqi Guo, Haomin Yan, Yunqing Qiu, Yan Lou
Alimentary Pharmacology & Therapeutics.2026;[Epub] CrossRef
Sodium taurocholate cotransporting polypeptide in HBV-related diseases: from underlying mechanisms to targeted therapies
Qiang Xie, Qingbo Liu, Xin Zheng, Leilei Fu, Hussein H. Aly, Bo Liu
Drug Discovery Today.2026; 31(3): 104664. CrossRef
Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect
Lihua Yang, Zibin Qiu, Xincheng Li, Jiachen Wei, Yike Ma, Weiqun Yuan, Qiuting Xu, Xiaoke Gu, Jingying Qiu
Bioorganic & Medicinal Chemistry.2026; 138: 118662. CrossRef
CD16+ γδ T cells mediate antibody-dependent cellular cytotoxicity and associate with viral control in chronic hepatitis B virus infection
Paulina E Schröter, Katja Steppich, Laura Fernández Carrera, Zheng Song, Sebastian Klein, Roni Souleiman, Melanie Urbanek-Quaing, Ayesha D Lietzau, Ansgar Schnieders, Erich Freyer, Birgit Bremer, Ximena León-Lara, Vicente Almeida, Rodrigo Gutierrez Jaureg
Gut.2026; : gutjnl-2025-337640. CrossRef
Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic Frontiers
Liping Xu, Huaqun Zhang, Bingchen Jiang, Yuanying Jiang, Hui Lu
Pharmaceutics.2026; 18(4): 446. CrossRef
Repurposing Product Nkabinde for Hepatitis B Virus Therapy: A Network Pharmacology and Molecular Docking Investigation
Samuel Chima Ugbaja, Siphathimandla Authority Nkabinde, Magugu Nkabinde, Nceba Gqaleni
Pharmaceuticals.2026; 19(4): 627. CrossRef
Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy”
Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen
Journal of Hepatology.2025; 82(5): e228. CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?
Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
Hepatology International.2025; 19(2): 304. CrossRef
Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider?
Shang-Chin Huang, Jia-Horng Kao
Expert Review of Gastroenterology & Hepatology.2025; 19(4): 371. CrossRef
Efficacy of Antiviral Therapy in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase: A Systematic Review and Meta‐Analysis
Yuting Diao, Yueying Zeng, Zhihao Huang, Chunfang You, Kevork M. Peltekian
Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Hepatitis B: Neue therapeutische Ansätze für eine funktionelle Heilung
Markus Cornberg, Ulrike Protzer
Deutsches Ärzteblatt Online.2025;[Epub] CrossRef
Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability
Yurong Yang, Fuling Xiao, Jianping Zuo, Li Yang, Youhong Hu, Wuhong Chen
Bioorganic & Medicinal Chemistry.2025; 128: 118259. CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies
Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
Hepatology International.2025; 19(4): 704. CrossRef
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure
Ana Verma, Raymond T. Chung
Current Opinion in HIV and AIDS.2025; 20(5): 449. CrossRef
Challenges and advances in clinical cure of chronic hepatitis B
Xu-Ling Liu, Yu-Lang Jiang, Ming-Yu Sun
World Chinese Journal of Digestology.2025; 33(9): 693. CrossRef
Small molecule HBV RNA destabilizing drugs: Drugs of the future or compounds from the past?
Timothy M. Block, Dimitar Gotchev, Yanming Du
Antiviral Research.2025; 244: 106288. CrossRef
Global strategies and actions to eliminate hepatitis B virus infection
Chih-Lin Lin, Jia-Horng Kao
Clinical and Molecular Hepatology.2025; 31(4): 1197. CrossRef
Morphometric and structural dynamic parameters of hepatitis viruses: implications for therapeutic and vaccine failure
Saganuwan Alhaji Saganuwan
Discover Viruses.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens
Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao
Hepatoma Research.2025;[Epub] CrossRef

13,679 View
543 Download
20 Web of Science
Crossref

Editorial

Viral hepatitis

Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”: Robert J. Wong; Clin Mol Hepatol 2025;31(2):603-605.
Published online October 29, 2024; DOI: https://doi.org/10.3350/cmh.2024.0929

Citations

Citations to this article as recorded by

Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TOR
Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
Clinical and Molecular Hepatology.2025; 31(2): e169. CrossRef

6,431 View
35 Download
1 Web of Science
Crossref

Correspondence

Viral hepatitis

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply: Hyeyeon Hong, Jonggi Choi; Clin Mol Hepatol 2024;30(2):272-273.
Published online February 21, 2024; DOI: https://doi.org/10.3350/cmh.2024.0123

Citations

Citations to this article as recorded by

Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(4): 1031. CrossRef

6,289 View
92 Download
1 Web of Science
Crossref

Original Articles

Viral hepatitis

Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program: Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi‐Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang, Yi-Hsiang Huang, Lee-Won Chong, Chien-Lin Chen, Chi-Chieh Yang, Sheng‐Shun Yang, Pin-Nan Cheng, Tsai-Yuan Hsieh, Jui-Ting Hu, Wen-Chih Wu, Chien-Yu Cheng, Guei-Ying Chen, Guo-Xiong Zhou, Wei-Lun Tsai, Chien-Neng Kao, Chih-Lang Lin, Chia-Chi Wang, Ta-Ya Lin, Chih‐Lin Lin, Wei-Wen Su, Tzong-Hsi Lee, Te-Sheng Chang, Chun-Jen Liu, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Cheng-Yuan Peng, Chun-Wei- Tsai, Chi-Yi Chen, Ming-Lung Yu, TACR Study Group; Clin Mol Hepatol 2024;30(1):64-79.
Published online November 21, 2023; DOI: https://doi.org/10.3350/cmh.2023.0287

Background/Aims
Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to investigate risk factors associated with DAA treatment failure. Machine-learning algorithms have been applied to discriminate subjects who may fail to respond to DAA therapy.
Methods
We analyzed the Taiwan HCV Registry Program database to explore predictors of DAA failure in HCV patients. Fifty-five host and virological features were assessed using multivariate logistic regression, decision tree, random forest, eXtreme Gradient Boosting (XGBoost), and artificial neural network. The primary outcome was undetectable HCV RNA at 12 weeks after the end of treatment.
Results
The training (n=23,955) and validation (n=10,346) datasets had similar baseline demographics, with an overall DAA failure rate of 1.6% (n=538). Multivariate logistic regression analysis revealed that liver cirrhosis, hepatocellular carcinoma, poor DAA adherence, and higher hemoglobin A1c were significantly associated with virological failure. XGBoost outperformed the other algorithms and logistic regression models, with an area under the receiver operating characteristic curve of 1.000 in the training dataset and 0.803 in the validation dataset. The top five predictors of treatment failure were HCV RNA, body mass index, α-fetoprotein, platelets, and FIB-4 index. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of the XGBoost model (cutoff value=0.5) were 99.5%, 69.7%, 99.9%, 97.4%, and 99.5%, respectively, for the entire dataset.
Conclusions
Machine learning algorithms effectively provide risk stratification for DAA failure and additional information on the factors associated with DAA failure.

Citations

Citations to this article as recorded by

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
Pei‐Chien Tsai, Chung‐Feng Huang, Ming‐Lun Yeh, Yu‐Ju Wei, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yi‐Hung Lin, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu
Alimentary Pharmacology & Therapeutics.2026; 63(8): 1119. CrossRef
The complexities of the pharmacotherapeutic management of chronic hepatitis C virus infection in hepatocellular carcinoma patients
Nicola Schiano Moriello, Biagio Pinchera, Ivan Gentile
Expert Opinion on Pharmacotherapy.2026; 27(8): 625. CrossRef
AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment
Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Xiangjun Meng, Jimmy Che-To Lai, Sang Hoon Ahn, Wenjing Pang, Grace Lai-Hung Wong, Lingfeng Zeng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim
Journal of Hepatology.2025; 82(3): 456. CrossRef
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan
Szu‐Jen Wang, Chung‐Feng Huang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Ming‐Jong Bair, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yu
The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes
Ming-Ying Lu, Yu-Ju Wei, Chih-Wen Wang, Po-Cheng Liang, Ming-Lun Yeh, Yi-Shan Tsai, Pei-Chien Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yi-Hung Lin, Tyng-Yuan Jang, Ming-Yen Hsieh, Zu-Yau Lin, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Ch
World Journal of Gastroenterology.2025;[Epub] CrossRef
Explainable machine learning for the assessment of donor grafts in liver transplantation
Liang Zhixing, Ye Linsen, Jiang Peng, Dong Siyi, Yu Haoyuan, Li Kun, Li Siqi, Hu Yongwei, Zhang Mingshen, Liu Wei, Li Hua, Yi Shuhong, Chen Guihua, Xu Xiao, Zheng Shusen, Yang Yang
Hepatology Research.2025; 55(6): 908. CrossRef
Role of risk factors and their variable types in predicting noise-induced hearing loss using artificial intelligence algorithms
Zhengheng Zhang, Longteng Jiang, Meibian Zhang, Yuan Pan, Jinnan Zheng, Anqi Liu, Weijiang Hu, Xin Jin
Hearing Research.2025; 465: 109353. CrossRef
Artificial Intelligence and Machine Learning Applications in Liver Disease
Bhargav Vemulapalli, Meghana Ghattu, Kavya Atluri, James Lee, Vinod Rustgi
Clinics in Liver Disease.2025; 29(4): 755. CrossRef
Unveiling the nexus between direct-acting antivirals in hepatitis C virus elimination and immune response
Aya I. Abdelaziz, Eman Abdelsameea, Sara A. Wahdan, Doaa Elsherbiny, Zeinab Zakaria, Samar S. Azab
Clinical and Experimental Medicine.2025;[Epub] CrossRef
Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Elimination
Daniela Toma, Lucreția Anghel, Diana Patraș, Anamaria Ciubară
Viruses.2025; 17(8): 1069. CrossRef
Nationwide hepatitis C virus microelimination in uremic patients undergoing maintenance hemodialysis in Taiwan
Chung-Feng Huang, Po-Cheng Liang, Yu-Ju Wei, Chao-Chun Wu, Shi-Lun Wei, Li-Ju Lin, Pei-Chun Hsieh, Tsui-Hsia Hsu, Maggie Shu-Mei Hsu, Ya-Xin Luo, Hsi-Chieh Chen, Tsu-Yun Ho, Shao-Hsuan Lin, Chia-Ling Liu, Kuo-Pen Cheng, John W. Ward, Ming-Lung Yu
Journal of the Formosan Medical Association.2025; 124: S102. CrossRef
Identifying new strategies to combat cytomegalovirus by integrating existing and innovative approaches in diagnosis and treatment
Nargiz Imamova, Ayten Feteliyeva, Adil M. Allahverdiyev
Future Virology.2025; 20(10): 379. CrossRef
Artificial intelligence in hepatology: A comprehensive scoping review of clinical applications, challenges, and future directions
Kirolos Eskandar
iLIVER.2025; 4(4): 100205. CrossRef
Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan
Chin-Wei Chang, Wei-Fan Hsu, Kuo-Chih Tseng, Chi-Yi Chen, Pin-Nan Cheng, Chao-Hung Hung, Ching-Chu Lo, Ming-Jong Bair, Chien-Hung Chen, Pei-Lun Lee, Chun-Yen Lin, Hsing-Tao Kuo, Chun-Ting Chen, Chi-Chieh Yang, Jee-Fu Huang, Chi-Ming Tai, Jui-Ting Hu, Chih
Digestive Diseases and Sciences.2024; 69(9): 3501. CrossRef
Bridging Real-World Data Gaps: Connecting Dots Across 10 Asian Countries
Guilherme Silva Julian, Wen-Yi Shau, Hsu-Wen Chou, Sajita Setia
JMIR Medical Informatics.2024; 12: e58548. CrossRef
The role of artificial intelligence in the management of liver diseases
Ming‐Ying Lu, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(11): 962. CrossRef
Real-World Experience, Effectiveness, and Safety of Direct-Acting Antivirals for the Treatment of Hepatitis C in Oman: A Cross-Sectional, Multicenter Study
Khalid M. Al-Naamani, Heba Omar, Said A. Al Busafi, Halima H. Al Shuaili, Zakariya Al-Naamani, Murtadha Al-Khabori, Elias A. Said, Abdullah H. AlKalbani, B. R. Kamath, Bashar Emad, Shahina Daar, Lolo Alhajri, Alya AlKalbani, Zainab AlFarsi, Haifa Alzuhaib
Journal of Clinical Medicine.2024; 13(23): 7411. CrossRef

13,445 View
213 Download
23 Web of Science
Crossref

Viral hepatitis

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide: Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi; Clin Mol Hepatol 2024;30(1):49-63.
Published online November 20, 2023; DOI: https://doi.org/10.3350/cmh.2023.0328

Background/Aims
Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised as to whether these differences affect long-term cardiovascular risk. Here, we aimed to evaluate the long-term risk of cardiovascular events in chronic hepatitis B (CHB) patients treated with TAF or TDF.
Methods
We retrospectively analyzed 4,124 treatment-naïve CHB patients treated with TDF (n=3,186) or TAF (n=938) between 2012 and 2022. The primary outcome was a composite endpoint of major adverse cardiovascular events (MACE), including myocardial infarction, ischemic stroke, and hospitalization for unstable angina or heart failure. Serial changes in lipid profiles between two treatments were also explored.
Results
The median age of the patients was 50.6 years, and 60.6% of the patients were male. At baseline, 486 (11.8%) and 637 (15.4%) of the patients had dyslipidemia and fatty liver, respectively. A total of 42 MACE occurred, with an annual incidence of 0.2%/100 person-years (PYs). At 1, 3, and 5 years, the cumulative risk of MACE was 0.4%, 0.8%, and 1.2% in patients treated with TDF, and 0.2%, 0.7%, and 0.7% in patients treated with TAF, respectively (p=0.538). No significant differences in the risk of MACE were observed between TDF and TAF. A multivariable analysis found that current smoker and a history of cardiovascular events were risk factors associated with an increased risk of MACE.
Conclusions
Patients treated with TAF had comparable risks of cardiovascular outcomes, defined as MACE, as patients treated with TDF.

Citations

Citations to this article as recorded by

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
Grace Lai‐Hung Wong, Edward Gane, Calvin Q. Pan, Scott Fung, Mang M. Ma, Namiki Izumi, Shalimar, Seng Gee Lim, Wan‐Long Chuang, Rajiv Mehta, Young‐Suk Lim, Leland J. Yee, John F. Flaherty, Frida Abramov, Hongyuan Wang, Maria Buti
Alimentary Pharmacology & Therapeutics.2026; 63(1): 132. CrossRef
Atherosclerotic Cardiovascular Risk in Patients with Chronic Hepatitis B: Tenofovir Disoproxil Fumarate Vs. Tenofovir Alafenamide: A Korean Nationwide Study
Jiwon Yang, Jihye Lim, Ye‐jee Kim, Hwa Jung Kim, Jonggi Choi
Journal of Medical Virology.2026;[Epub] CrossRef
Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study
Jonggi Choi, Junqing Xu, Vy H. Nguyen, Eric Przybyszewski, Daniel S. Pratt, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung
Hepatology.2026;[Epub] CrossRef
A Comparative Study of Entecavir and Tenofovir Alafenamide on Quantitative HBsAg Reduction in Patients With CHB
Jungnam Lee, Young‐Joo Jin
Journal of Medical Virology.2026;[Epub] CrossRef
Evaluating fracture risk with TDF in elderly patients with hepatitis B: A Korean perspective
Yoon E. Shin, Jae Young Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim
Journal of Hepatology.2025; 82(6): e301. CrossRef
Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B
Log Young Kim, Jae Young Kim, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
Journal of Medical Virology.2025;[Epub] CrossRef
Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis
Jae-Young Kim, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Hepatology International.2025; 19(4): 959. CrossRef
Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta‐Analysis
Ping‐Yu Hsu, Hui‐Chen Su, Mi‐Chia Ma, Chien‐An Chen, Sin‐Yi Yu, Yi‐Ming Hua
Journal of Medical Virology.2025;[Epub] CrossRef
Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B
Witchayaporn Praguylertluck, Apichat Kaewdech, Naichaya Chamroonkul, Teerha Piratvisuth, Pimsiri Sripongpun, Tyng-Yuan Jang
PLOS One.2025; 20(5): e0324897. CrossRef
Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis
Yuan-Hai Zhou, Nan Cai, Yu-Xin Chen, Yong-Lu Su, Peng Hu
Frontiers in Pharmacology.2025;[Epub] CrossRef
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk
Ankur Jindal, Manoj Kumar
Hepatology International.2025; 19(4): 701. CrossRef
Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis
Yunmi Ko, Byeong Geun Song, Hyunjae Shin, Youngsu Park, Jeayeon Park, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Dong Hyun Sinn, Yoon Jun Kim, Jung-Hwan Yoon, Seung Shin Park, Moon Haeng Hur, Jeong-Hoon Lee
Osteoporosis International.2025; 36(8): 1391. CrossRef
Blood pressure and metabolic outcomes after efavirenz‐ or dolutegravir‐based therapy started in acute HIV infection
Phillip Chan, Sarah Moreland, Carlo Sacdalan, Donn J. Colby, Ferron Ocampo, Pathariya Promsena, Somchai Sriplienchan, Jarawee Wattana, Jintana Intasan, Nittaya Phanuphak, Sandhya Vasan, Robert Paul, Lydie Trautmann, Serena Spudich, Eugène Kroon
HIV Medicine.2025; 26(10): 1619. CrossRef
Pharmacovigilance analysis of metabolic and nutritional adverse reactions associated with entecavir and tenofovir using the FDA adverse event reporting system database
Haomin Zhu, Baolong Ding, Zhuying Jing, Hongting Yao, Yue Li, Lihong Gao, Yulu Zhu, Xin Li
International Journal of Clinical Pharmacy.2025; 47(5): 1510. CrossRef
Antiviral Therapy Reduces Dyslipidemia and Cardiovascular Risk in Chronic Hepatitis B: TDF as the Most Effective Agent
Hyuk Kim, Jae‐Young Kim, Hyun Bin Choi, Ji‐Soo Lee, Yoon E. Shin, Jeong‐Ju Yoo, Sang Gyune Kim, Young‐Seok Kim
Journal of Medical Virology.2025;[Epub] CrossRef
Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate
Jiwon Yang, Jihye Lim, Ye‐Jee Kim, Hwa Jung Kim, Jonggi Choi
Liver International.2025;[Epub] CrossRef
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
Hyeyeon Hong, Jonggi Choi
Clinical and Molecular Hepatology.2024; 30(2): 272. CrossRef
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(2): 144. CrossRef
Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients
Wenjuan Zhao, Yi Liu, Mengdi Zhang, Zixin Cui, Zhan Qu, Yiyang Li, Meijuan Wan, Wen Wang, Yunru Chen, Lei Shi, Jianzhou Li, Feng Ye
Frontiers in Medicine.2024;[Epub] CrossRef
Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(4): 1031. CrossRef
Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B
Fei Cao, Tao Fan, Xue Jiang, Jian Wang, Yilin Liu, Li Zhu, Ye Xiong, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Xiaomin Yan, Jie Li, Xingxiang Liu, Chuanwu Zhu, Rui Huang, Chao Wu
Virology Journal.2024;[Epub] CrossRef
Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
Maria Buti, Young‐Suk Lim, Henry Lik Yuen Chan, Kosh Agarwal, Patrick Marcellin, Maurizia R. Brunetto, Wan‐Long Chuang, Harry L. A. Janssen, Scott K. Fung, Namiki Izumi, Maciej S. Jablkowski, Dzhamal Abdurakhmanov, Frida Abramov, Hongyuan Wang, Irina Botr
Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1573. CrossRef

9,048 View
298 Download
25 Web of Science
Crossref

Letter to the Editor

Viral hepatitis

Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”: Chi Hsiao, Yung-Po Liaw; Clin Mol Hepatol 2024;30(1):109-110.
Published online October 11, 2023; DOI: https://doi.org/10.3350/cmh.2023.0373

4,694 View
56 Download

Original Article

Viral hepatitis

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma: Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee; Clin Mol Hepatol 2023;29(3):794-809.
Published online May 17, 2023; DOI: https://doi.org/10.3350/cmh.2023.0057

Background/Aims
Chronic hepatitis B (CHB) is a risk factor for non-Hodgkin lymphoma (NHL). Our recent study suggested that antiviral treatment may reduce the incidence of NHL in CHB patients. This study compared the prognoses of hepatitis B virus (HBV)-associated diffuse large B-cell lymphoma (DLBCL) patients receiving antiviral treatment and HBV-unassociated DLBCL patients.
Methods
This study comprised 928 DLBCL patients who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) at two referral centers in Korea. All patients with CHB received antiviral treatment. Time-to-progression (TTP) and overall survival (OS) were the primary and secondary endpoints, respectively.
Results
Among the 928 patients in this study, 82 were hepatitis B surface antigen (HBsAg)-positive (the CHB group) and 846 were HBsAg-negative (the non-CHB group). The median follow-up time was 50.5 months (interquartile range [IQR]=25.6–69.7 months). Multivariable analyses showed longer TTP in the CHB group than the non-CHB group both before inverse probability of treatment weighting (IPTW; adjusted hazard ratio [aHR]=0.49, 95% confidence interval [CI]=0.29–0.82, p=0.007) and after IPTW (aHR=0.42, 95% CI=0.26–0.70, p<0.001). The CHB group also had a longer OS than the non-CHB group both before IPTW (HR=0.55, 95% CI=0.33–0.92, log-rank p=0.02) and after IPTW (HR=0.53, 95% CI=0.32–0.99, log-rank p=0.02). Although liver-related deaths did not occur in the non-CHB group, two deaths occurred in the CHB group due to hepatocellular carcinoma and acute liver failure, respectively.
Conclusions
Our findings indicate that HBV-associated DLBCL patients receiving antiviral treatment have significantly longer TTP and OS after R-CHOP treatment than HBV-unassociated DLBCL patients.

Citations

Citations to this article as recorded by

Chronic hepatitis b coinfection and survival in pediatric T-ALL: A propensity-matched analysis
Yutong Zhang, Ruihong Wu, Yuan Zhang, Yufei Zhao, Xiaodan Zhong, Xianmei Jin, Chao Zhang, Jian Chang
iScience.2026; 29(1): 114319. CrossRef
Concurrent antiviral–immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B‐cell lymphoma: A multicentre cohort study
Yuxiao Zhao, Jingjing Guo, Xiran Wang, Lei Cao, Yi Xia, Haorui Shen, Ran Li, Ping Wu, Hongling Mi, Jing Zhang, Jianyong Li, Hailing Liu, Xiaoyan Qu, Lei Fan
British Journal of Haematology.2026;[Epub] CrossRef
Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”
Chi Hsiao, Yung-Po Liaw
Clinical and Molecular Hepatology.2023; 30(1): 109. CrossRef

8,943 View
189 Download
4 Web of Science
Crossref

Review

Viral hepatitis

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm: Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao; Clin Mol Hepatol 2023;29(4):869-890.
Published online March 14, 2023; DOI: https://doi.org/10.3350/cmh.2022.0420

Abstract
PDF

Nucleos(t)ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at seroclearance of the hepatitis B surface antigen (HBsAg). As an alternative strategy, finite NA therapy without the prerequisite of HBsAg seroclearance has been proposed to allow treatment cessation in patients with sustained undetectable HBV viremia for two to three years. However, reactivation of viral replication almost always follows NA withdrawal. Whereas HBV reactivation might facilitate HBsAg seroclearance in some, it could lead to serious acute flare-ups in a certain proportion of patients. Occurrence and consequences of NA withdrawal flares are complicated with various factors involving the virus, host, and treatment. Accurate risk prediction for severe flares following NA cessation is essential to ensure patient safety. The risks of life-threatening flares in patients who discontinued NA according to the stopping rules of current guidelines or local reimbursement policies have recently been quantitatively estimated in large-scale studies, which also provided empirical evidence to help identify vulnerable patients at risk of devastating outcomes. Moreover, risk predictors were further explored and validated to hopefully aid in patient selection and management. In this narrative review with a focus on patient safety, we summarize and discuss current literature on the incidence of severe flares following NA cessation, risk stratification for candidate selection, rules of posttreatment monitoring, and indications for treatment resumption. We also share our thoughts on the limitations of existing knowledge and suggestions for future research.

Citations

Citations to this article as recorded by

Chronic Hepatitis B Infection: Patient Guidance
Lung‐Yi Mak, Jimmy Che‐To Lai, Ken Liu, Rashid Lui, Sakkarin Chirapongsathorn, Kuo Chao Yew, Mara Teresa Panlilio, Cosmas Rinaldi Adithya Lesmana, Ruveena Bhavani Rajaram, Liang Shen, Desmond Cheung, Lung‐Fai Wong, Hye Won Lee, Madhumita Premkumar, Anand
Journal of Gastroenterology and Hepatology.2026; 41(1): 61. CrossRef
Mitochondrial metabolic remodeling predicts therapeutic response to PegIFN-α in chronic hepatitis B
Yingying Zhang, Xiu Han, Chengyu Xu, Yahui Song, Jinghan Zhu, Ruoran Zhou, Yiling Chen, Mingming Liu, Junchi Xu, Xiangwei Wu, Qingzhen Han, Zutao Chen
Frontiers in Cellular and Infection Microbiology.2026;[Epub] CrossRef
Epstein–Barr Virus and Hepatitis E Virus in an Immunocompetent Adult: A Rare Case Report
Philippe Attieh, Antonio Al Hazzouri, Karam Karam, Ihab I. El Hajj, Elias Fiani
Clinical Case Reports.2026;[Epub] CrossRef
Research Progress on the Recompensation of Liver Cirrhosis
源高
Advances in Clinical Medicine.2026; 16(03): 2709. CrossRef
Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
Ying‐Nan Tsai, Jia‐Ling Wu, Cheng‐Hao Tseng, Tzu‐Haw Chen, Ying‐Chu Chung, Mindie H. Nguyen, Jaw‐Town Lin, Katsuya Nagaoka, Yasuhito Tanaka, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2026; 64(1): 89. CrossRef
Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka
Hepatology Research.2026; 56(6): 903. CrossRef
Nucleos(t)ide Analog Treatment Discontinuation in Chronic Hepatitis B Virus Infection: A Systematic Literature Review
Robert Gish, Kosh Agarwal, Anadi Mahajan, Supriya Desai, Saifuddin Kharawala, Rob Elston, Joyeta Das, Stuart Kendrick, Vera Gielen
Gastro Hep Advances.2025; 4(1): 100536. CrossRef
Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF
Hyuk Kim, Jae-Young Kim, Yoon E. Shin, Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Scientific Reports.2025;[Epub] CrossRef
Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
Ying‐Nan Tsai, Jia‐Ling Wu, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2025; 61(7): 1244. CrossRef
Association Between Elevation of Serum Alanine Aminotransferase and HBsAg Seroclearance After Nucleos(t)ide Analog Withdrawal
Ying‐Nan Tsai, Jia‐Ling Wu, Cheng‐Hao Tseng, Shang‐Chen Tseng, Chih‐Lung Hung, Mindie H. Nguyen, Jaw‐Town Lin, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2025; 61(7): 1208. CrossRef
Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
Ying‐Nan Tsai, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2025; 61(8): 1424. CrossRef
Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B
Cheng‐Hao Tseng, Teng‐Yu Lee, Chi‐Yi Chen, Chung‐Feng Huang, Po‐Yueh Chen, Tyng‐Yuan Jang, Tzeng‐Huey Yang, Chia‐Ching Wu, Yao‐Chun Hsu
Journal of Gastroenterology and Hepatology.2025; 40(5): 1245. CrossRef
Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TOR
Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin
Clinical and Molecular Hepatology.2025; 31(2): e169. CrossRef
Impact of nucleos(t)ide analogue therapy on the incidence of Alzheimer’s disease in patients with chronic hepatitis B virus infection
Jihye Lim, Hyundam Gu, Hyunji Sang, Su Jin Jeong, Ha Il Kim
Alzheimer's Research & Therapy.2025;[Epub] CrossRef
Association of nucleos(t)ide analogue therapy with Parkinson disease in chronic hepatitis B patients
Jihye Lim, Hyo Young Lee, Hyunji Sang, Su Jin Jeong, Ha Il Kim
Scientific Reports.2025;[Epub] CrossRef
Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study
Shinya Kawamatsu, Kiran K. Rai, Vera Gielen, Amisha Patel, Olivia Massey, Seth W. Anderson, Yutaka Handa, Ethan Yichen Lee, Poppy Payne, Isabel Jimenez, Kejsi Begaj, Shayon Salehi, Jun Inoue, Afisi S. Ismaila
Journal of Viral Hepatitis.2025;[Epub] CrossRef
Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
Scientific Reports.2025;[Epub] CrossRef
Small nucleic acid drugs-the dawn of functional cure of chronic hepatitis B
Lu Zhang, Yu Cao, Sijing Zhuang, Jingjing Sun, Qiao Tong, Jianjun Xi, Shourong Liu, Rangxiao Zhuang
Frontiers in Pharmacology.2025;[Epub] CrossRef
Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir
Hyuk Kim, Jae Young Kim, Hye-Jin Yoo, Log Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Scientific Reports.2025;[Epub] CrossRef
Global strategies and actions to eliminate hepatitis B virus infection
Chih-Lin Lin, Jia-Horng Kao
Clinical and Molecular Hepatology.2025; 31(4): 1197. CrossRef
Letter: Estimating the incidence of HBsAg seroclearance after cessation of tenofovir and entecavir ‐ potential influence of censored observation
Ying‐Nan Tsai, Jia‐Ling Wu, Yao‐Chun Hsu
Alimentary Pharmacology & Therapeutics.2024; 59(1): 136. CrossRef
Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research
Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu
Clinical and Molecular Hepatology.2024; 30(2): 276. CrossRef
Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen
Chen-Te Huang, Tai-Chung Tseng
Clinical and Molecular Hepatology.2024; 30(2): 154. CrossRef
Finite therapy of chronic hepatitis B infection: Cons
Yao-Chun Hsu
Clinical Liver Disease.2024;[Epub] CrossRef
Current perspectives of viral hepatitis
Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou,
World Journal of Gastroenterology.2024; 30(18): 2402. CrossRef
Extended analysis on peripheral blood cytokines correlated with hepatitis B virus viral load in chronically infected patients – a systematic review and meta-analysis
Marina Manea, Ion Mărunțelu, Ileana Constantinescu
Frontiers in Medicine.2024;[Epub] CrossRef
Review of the Effects of Antiviral Therapy on Hepatitis B/C-Related Mortality and the Regression of Fibrosis
Stephen Sinclair, Sean Shearen, Youssef Ghobrial, George Trad, Syed Abdul Basit, David Shih, John K. Ryan
Viruses.2024; 16(10): 1531. CrossRef
Real‐World Pharmacovigilance Study Identifies Drugs Linked to Hepatitis B Virus Reactivation
Jie Wang, He Jiang, Guoqi Zhang, Xiahong Dai, Hainv Gao, Lanjuan Li
Journal of Medical Virology.2024;[Epub] CrossRef
Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population‐based cohort study
Yao‐Chun Hsu, Yi‐Hsian Lin, Teng‐Yu Lee, Mindie H. Nguyen, Cheng‐Hao Tseng, Hsiu J. Ho, Feng‐Yu Kao, Jaw‐Town Lin, Chen‐Yi Wu, Chun‐Ying Wu
Alimentary Pharmacology & Therapeutics.2023; 58(4): 463. CrossRef
Editorial: Mitigating the risk of severe hepatitis flare following nucleoside analogue discontinuation—Insights from a real‐world study. Authors' reply
Yao‐Chun Hsu, Chun‐Ying Wu
Alimentary Pharmacology & Therapeutics.2023; 58(5): 550. CrossRef
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection—Authors' reply
Yao‐Chun Hsu, Mindie H. Nguyen, Chun‐Ying Wu
Alimentary Pharmacology & Therapeutics.2023; 58(7): 733. CrossRef

11,835 View
252 Download
26 Web of Science
Crossref

Editorial

Viral hepatitis

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers: Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip; Clin Mol Hepatol 2023;29(1):113-117.
Published online October 31, 2022; DOI: https://doi.org/10.3350/cmh.2022.0333

Citations

Citations to this article as recorded by

Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance
Han Ah. Lee, Hyun Woong Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim
Journal of Gastroenterology and Hepatology.2025; 40(7): 1675. CrossRef
Long-Term Safety and Efficacy of Tenofovir Alafenamide in Chronic Hepatitis B: Raising the Need for Studies on Functional Cure—Editorial on “Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B”
Soon Kyu Lee
The Korean Journal of Gastroenterology.2025; 85(3): 245. CrossRef
Hepatocellular carcinoma surveillance after HBsAg seroclearance
Jimmy Che-To Lai, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Exploration of Digestive Diseases.2024; : 175. CrossRef
Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure
Leeor Hershkovich, Louis Shekhtman, Michel Bazinet, Victor Pântea, Gheorge Placinta, Scott J. Cotler, Andrew Vaillant, Harel Dahari
Hepatology Communications.2023;[Epub] CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clinical and Molecular Hepatology.2023; 29(1): 191. CrossRef
Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus
Daniel G. Sausen, Oren Shechter, William Bietsch, Zhenzhen Shi, Samantha M. Miller, Elisa S. Gallo, Harel Dahari, Ronen Borenstein
International Journal of Molecular Sciences.2022; 23(24): 15973. CrossRef

7,273 View
123 Download
5 Web of Science
Crossref

Original Articles

Viral hepatitis

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis: Chen-Hua Liu, Chi-Yi Chen, Wei-Wen Su, Chun-Jen Liu, Ching-Chu Lo, Ke-Jhang Huang, Jyh-Jou Chen, Kuo-Chih Tseng, Chi-Yang Chang, Cheng-Yuan Peng, Yu-Lueng Shih, Chia-Sheng Huang, Wei-Yu Kao, Sheng-Shun Yang, Ming-Chang Tsai, Jo-Hsuan Wu, Po-Yueh Chen, Pei-Yuan Su, Jow-Jyh Hwang, Yu-Jen Fang, Pei-Lun Lee, Chi-Wei Tseng, Fu-Jen Lee, Hsueh-Chou Lai, Tsai-Yuan Hsieh, Chun-Chao Chang, Chung-Hsin Chang, Yi-Jie Huang, Jia-Horng Kao; Clin Mol Hepatol 2021;27(4):575-588.
Published online July 13, 2021; DOI: https://doi.org/10.3350/cmh.2021.0155

Background/Aims
Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited.
Methods
We included 107 patients with Child-Pugh B/C HCV-related cirrhosis receiving SOF/VEL plus RBV for 12 weeks in Taiwan. The sustained virologic response rates at off-treatment week 12 (SVR₁₂) for the evaluable population (EP), modified EP, and per-protocol population (PP) were assessed. Thesafety profiles were reported.
Results
The SVR₁₂ rates in the EP, modified EP and PP were 89.7% (95% confidence interval [CI], 82.5–94.2%), 94.1% (95% CI, 87.8–97.3%), and 100% (95% CI, 96.2–100%). Number of patients who failed to achieve SVR₁₂ were attributed to virologic failures. The SVR₁₂ rates were comparable regardless of patient characteristics. One patient discontinued treatment because of adverse events (AEs). Twenty-four patients had serious AEs and six died, but none were related to SOF/VEL or RBV. Among the 96 patients achieving SVR₁₂, 84.4% and 64.6% had improved Child-Pugh and model for endstage liver disease (MELD) scores. Multivariate analysis revealed that a baseline MELD score ≥15 was associated with an improved MELD score of ≥3 (odds ratio, 4.13; 95% CI, 1.16–14.71; P=0.02). Patients with chronic kidney disease (CKD) stage 1 had more significant estimated glomerular filtration rate declines than patients with CKD stage 2 (-0.42 mL/min/1.73 m²/month; P=0.01) or stage 3 (-0.56 mL/min/1.73 m²/month; P<0.001).
Conclusions
SOF/VEL plus RBV for 12 weeks is efficacious and well-tolerated for Child-Pugh B/C HCV-related cirrhosis.

Citations

Citations to this article as recorded by

2025 KASL clinical practice guidelines for management of hepatitis C
Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung
Clinical and Molecular Hepatology.2026; 32(1): 1. CrossRef
Comparison of Child-Pugh and MELD scores in predicting survival of hepatocellular carcinoma patients with splenomegaly undergoing TACE: a real-world study
Lu Xu, Bo Jiang, Yicheng Ma, Jianhua Pan, Ming Liang, Qianqian Du, Haotian Wu, Zhiheng Cheng, Dong Lu
Frontiers in Medicine.2026;[Epub] CrossRef
Role of etiological therapy in achieving recompensation of decompensated liver cirrhosis
Dmitry V Garbuzenko
World Journal of Hepatology.2025;[Epub] CrossRef
Effectiveness of etiotropic therapy in achieving recompensation of cirrhosis
D.V. Garbuzenco
Russian Journal of Evidence-Based Gastroenterology.2025; 14(2): 68. CrossRef
Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study
Jae Hyun Yoon, Chang Hun Lee, Hoon Gil Jo, Ju-Yeon Cho, Jin Dong Kim, Jin Won Kim, Ga Ram You, Sung Bum Cho, Sung Kyu Choi
Viruses.2025; 17(7): 949. CrossRef
Efficacy and Safety of Velpatasvir Plus Sofosbuvir With or Without Ribavirin in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta‐Analysis
Jing Xiao, Xinnian Zhang, Xiaozhou Mao, Shunhao Lai, Shuangli Li, Yunjian Sheng
Journal of Viral Hepatitis.2025;[Epub] CrossRef
Oral carbohydrate intake before selective laparoscopic liver resection reduces insulin resistance and enhances recovery
Hongqiong Li
American Journal of Translational Research.2025; 17(8): 6080. CrossRef
Recent Advances in the Treatment of Chronic Hepatitis C
Suk Bae Kim
The Korean Journal of Gastroenterology.2025; 85(4): 475. CrossRef
Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study
Mengyue Li, Yiting Li, Ying Zhang, Xiangyang Wang, Chaoshuang Lin
Medicine.2024; 103(7): e37212. CrossRef
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review
Chen-Hua Liu, Yu-Ping Chang, Jia-Horng Kao
Expert Opinion on Pharmacotherapy.2024; 25(12): 1691. CrossRef
Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients
Jiayi Wang, Lingyao Du, Dongmei Zhang, Chen Zhou, Yilan Zeng, Miao Liu, Xing Cheng, Xiaona Song, Han Chen, Ning Han, Enqiang Chen, Hong Tang
Journal of Virus Eradication.2024; 10(4): 100571. CrossRef
Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response
Chen‐Hua Liu, Chun‐Jen Liu, Tung‐Hung Su, Tai‐Chung Tseng, Pei‐Jer Chen, Jia‐Horng Kao
Advances in Digestive Medicine.2023; 10(1): 34. CrossRef
Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir‐velpatasvir
Pei‐Kai Su, Te‐Sheng Chang, Shui‐Yi Tung, Kuo‐Liang Wei, Chien‐Heng Shen, Yung‐Yu Hsieh, Wei‐Ming Chen, Yi‐Hsing Chen, Chun‐Hsien Chen, Chih‐Wei Yen, Huang‐Wei Xu, Wei‐Ling Tung, Kao‐Chi Chang
Advances in Digestive Medicine.2023; 10(3): 150. CrossRef
Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue, Sarah Krull Abe, Shuhei Nomur
Scientific Reports.2023;[Epub] CrossRef
Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
Jeong Heo, Yoon Jun Kim, Sung Wook Lee, Youn-Jae Lee, Ki Tae Yoon, Kwan Soo Byun, Yong Jin Jung, Won Young Tak, Sook-Hyang Jeong, Kyung Min Kwon, Vithika Suri, Peiwen Wu, Byoung Kuk Jang, Byung Seok Lee, Ju-Yeon Cho, Jeong Won Jang, Soo Hyun Yang, Seung W
The Korean Journal of Internal Medicine.2023; 38(4): 504. CrossRef
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hézode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Sam
Viruses.2023; 15(10): 2026. CrossRef
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus–related cirrhosis
Chen-Hua Liu, Chun-Jen Liu, Jia-Horng Kao
Journal of the Chinese Medical Association.2022; 85(5): 647. CrossRef
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo
The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef
HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV
Kilian Weigand, Georg Peschel, Jonathan Grimm, Martina Müller, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler
Biomedicines.2022; 10(12): 3152. CrossRef

15,286 View
1,035 Download
17 Web of Science
Crossref

Viral hepatitis

The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients: Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan; Clin Mol Hepatol 2021;27(3):474-485.
Published online February 19, 2021; DOI: https://doi.org/10.3350/cmh.2021.0015

Background/Aims
Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on disease severity is commonly practiced, the efficacy of such approach remained uncertain. We aimed to compare the impact of unrestricted access to direct-acting antiviral (DAA) among incarcerated HCV-infected patients in Singapore.
Methods
In this retrospective study, we reviewed all incarcerated HCV-infected patients treated in our hospital during the restricted DAA era (2013–2018) and unrestricted DAA access era (2019). Study outcomes included the rate of sustained virological response (SVR), treatment completion and treatment default. Subgroup analysis was performed based on the presence of liver cirrhosis, HCV genotype and HCV treatment types.
Results
A total of 1,001 HCV patients was followed-up for 1,489 person-year. They were predominantly male (93%) with genotype-3 HCV infection (71%), and 38% were cirrhotic. The overall SVR during the restricted DAA access era and unrestricted DAA access era were 92.1% and 99.1%, respectively. Unrestricted access to DAA exponentially improved the treatment access among HCV-infected patients by 460%, resulting in a higher SVR rate (99% vs. 92%, P=0.003), higher treatment completion rate (99% vs. 93%, P<0.001) and lower treatment default rate (1% vs. 9%, P<0.001).
Conclusion
In this large cohort of incarcerated HCV-infected patients, we demonstrated that unrestricted access to DAA is an impactful strategy to allow rapid treatment up-scale in HCV micro-elimination.

Citations

Citations to this article as recorded by

Editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
Yan Ling Ong, Apichat Kaewdech, Daniel Q Huang, Yu Jun Wong
Clinical and Molecular Hepatology.2026; 32(1): 407. CrossRef
Hepatitis C elimination in Singapore: Current status and future directions
JWE Quek, D Varun, JH Loo, KC Yew, J Hsiang, PH Thurairajah, C‐K Tan, R Kumar, YJ Wong
Journal of Gastroenterology and Hepatology.2025; 40(1): 339. CrossRef
Status of hepatitis B virus and hepatitis C elimination in Singapore: a call for action
Yu Jun Wong, Daniel Huang
Singapore Medical Journal.2025; 66(7): 376. CrossRef
Elimination of chronic viral hepatitis C in correctional health
Rahul Kumar, Yu Jun Wong, Jessica Tan
Singapore Medical Journal.2025; 66(Suppl 1): S70. CrossRef
Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis
Joo Wei Ethan Quek, Jing Hong Loo, En Qi Lim, Ambrose Hon-Lam Chung, Abu Bakar Bin Othman, Jarell Jie-Rae Tan, Scott Barnett, Mindie H. Nguyen, Yu Jun Wong
eClinicalMedicine.2024; 74: 102727. CrossRef
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
Lung-Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, Kuo Chao Yew, Nobuharu Tamaki, Ruveena Bhavani Rajaram, Mara Teresa Panlilio, Rashid Lui, Hye Won Lee, Jimmy Che-To Lai, Anand V. Kulkarni, Madhumita Premkumar, Cosmas Rinaldi Adithya Lesmana, Yao Chun Hsu,
Nature Reviews Gastroenterology & Hepatology.2024; 21(12): 834. CrossRef
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients
Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani
Clinical and Molecular Hepatology.2023; 29(1): 135. CrossRef
Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue, Sarah Krull Abe, Shuhei Nomur
Scientific Reports.2023;[Epub] CrossRef
Access to Hepatitis C Treatment during and after Incarceration in New Jersey, United States: A Qualitative Study
Samir Kamat, Sankeerth Kondapalli, Shumayl Syed, Gabrielle Price, George Danias, Ksenia Gorbenko, Joel Cantor, Pamela Valera, Aakash K. Shah, Matthew J. Akiyama
Life.2023; 13(4): 1033. CrossRef
Minimal monitoring is a safe but underutilised strategy for hepatitis C virus treatment in Singapore
Wei Xuan Tay, Samantha Jingyun Koh, Francis Kok Ban Teh, Yu Bin Tan, Tian Yu Qiu, Linn War Mai, Vivien Li Xin Wong, Jessica Tan, Andrew Kwek, Kwong Ming Fock, Tiing Leong Ang, Rahul Kumar, Yu Jun Wong
Annals of the Academy of Medicine, Singapore.2023; 52(6): 321. CrossRef
HCV Microelimination for High-risk Special Populations
Chung-Feng Huang, Guan-Jhou Chen, Chien-Ching Hung, Ming-Lung Yu
The Journal of Infectious Diseases.2023; 228(Supplement): S168. CrossRef
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis
Jing Hong Loo, Wen Xin Flora Xu, Jun Teck Low, Wei Xuan Tay, Le Shaun Ang, Yew Chong Tam, Prem Harichander Thurairajah, Rahul Kumar, Yu Jun Wong
World Journal of Hepatology.2022; 14(6): 1248. CrossRef
HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV
Kilian Weigand, Georg Peschel, Jonathan Grimm, Martina Müller, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler
Biomedicines.2022; 10(12): 3152. CrossRef
Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers–Led Model for HCV Microelimination in Thailand
Ruamthip Supanan, Win Min Han, Weerakit Harnpariphan, Thornthun Ueaphongsukkit, Sasiwimol Ubolyam, Jiratchaya Sophonphan, Pisit Tangkijvanich, Sombat Thanprasertsuk, Anchalee Avihingsanon
JAIDS Journal of Acquired Immune Deficiency Syndromes.2021; 88(5): 465. CrossRef

12,333 View
150 Download
14 Web of Science
Crossref

Editorial

Viral hepatitis

Drug-drug interactions with direct-acting antivirals — less is more: Grace Lai-Hung Wong; Clin Mol Hepatol 2021;27(1):81-82.
Published online December 3, 2020; DOI: https://doi.org/10.3350/cmh.2020.0278

Citations

Citations to this article as recorded by

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo
The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef

7,112 View
110 Download
1 Web of Science
Crossref

Review

Viral hepatitis

Current and future strategies for the treatment of chronic hepatitis C: Omar Alshuwaykh, Paul Y. Kwo; Clin Mol Hepatol 2021;27(2):246-256.
Published online December 3, 2020; DOI: https://doi.org/10.3350/cmh.2020.0230

Abstract
PDF

Chronic hepatitis C infection is a major cause of liver disease and hepatocellular carcinoma worldwide. While hepatitis C has been treated for decades with some success, the introduction of direct acting antiviral agents has revolutionized the treatment of hepatitis C with finite, highly effective, well-tolerated therapy and there are few populations that cannot be successfully treated now or are complicated to manage. The World Health Organization has released elimination targets in an effort to eliminate viral hepatitis and reduce dramatically the morbidity and mortality caused by both viral hepatitis. While hepatitis C is straightforward to treat, it remains problematic to eliminate on a global scale. Diagnosis of hepatitis C remains the major gap in the cascade of care and numerous screening strategies will be required to reduce this gap. While historically, treatment of hepatitis C has been centralized, decentralized approaches will be required to diagnose, evaluate, and link to care the large population of individuals worldwide with hepatitis C across low-, middle-, and high-income countries. With the introduction of multiple pangenotypic treatment options and reduced cost for these therapies, assessment and treatment for those with hepatitis C has been simplified and made more accessible worldwide. There are multiple populations for whom care models are being developed and refined, including those when inject drugs, those who are incarcerated, those who present with sexually transmitted disease including the men who have sex with men population, amongst many others. While a vaccine for hepatitis C remains elusive these efforts continue. Multiple successful elimination efforts have been reported.

Citations

Citations to this article as recorded by

Mapping HLA class I and II allele associations with hepatitis C related liver disease progression in an Egyptian cohort
Mai M. Lotfy, Noura A. A. Ebrahim, Mohamed El-Kassas, Ashraf Omar Abdel-Aziz, Dalia Abdelhamid Omran, Dalia Abdelfatah, Ahmed B. Barakat, Amira Salah El-Din Youssef, Auhood Nassar, Hany K. Soliman, Abdel Rahman N. Zekri
Discover Oncology.2026;[Epub] CrossRef
Etiologic, epidemic, medical and economic aspects of hepatocellular carcinoma
N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
Сибирский научный медицинский журнал.2025; 45(1): 6. CrossRef
Current treatments and the future of nanomedicine in hepatitis C
Drue Julien, Horacio Bach
Nanomedicine.2025; 20(13): 1589. CrossRef
Metabolic dysfunction, cirrhosis, and HCV genotype 3a drive type 2 diabetes risk in chronic hepatitis C: a Southern Chinese cohort study
Zhanyi Li, Yuyu Ye, Yeqiong Zhang, Wenxiong Xu, Ying Liu
BMC Gastroenterology.2025;[Epub] CrossRef
Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study
Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim
Medicina.2025; 61(9): 1601. CrossRef
Etiological, Epidemiological, and Medical-Economic Aspects of Hepatocellular Carcinoma (A Review)
N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
Cell and Tissue Biology.2025; 19(6): 525. CrossRef
Impact of a Simplified Care Model on Direct-acting Antiviral Treatment for Hepatitis C Virus-positive People in Addiction Care: A Retrospective Review of the trueNorth Medical Centres Database
Chris Cavacuiti, Roger Gaertner, Veeral Gandhi
Canadian Journal of Addiction.2024; 15(2): 50. CrossRef
State of Knowledge on Sexually Transmitted Infections among Health Professionals and Health Sciences Students in France
Marine Chlebus, Laurence Boyer, Sébastien Doerper, Tristan Hergot, Mihayl Varbanov
Venereology.2024; 3(2): 63. CrossRef
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review
Malik Sallam, Roaa Khalil
Microorganisms.2024; 12(6): 1035. CrossRef
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
Won Sohn, Yong-Han Paik
Clinical and Molecular Hepatology.2023; 29(1): 182. CrossRef
Case report: Chronic hepatitis C with anti-HCV positive and serum HCV RNA negative
Huihui Lu, Wen Deng, Yao Lu, Lu Zhang, Yao Xie, Minghui Li
Gastroenterology & Endoscopy.2023; 1(2): 120. CrossRef
Management of in- and out-of-hospital screening for hepatitis C
Jing Zhou, Fa-Da Wang, Lan-Qing Li, En-Qiang Chen
Frontiers in Public Health.2023;[Epub] CrossRef
Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong
Clinical and Molecular Hepatology.2023; 29(2): 496. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clinical and Molecular Hepatology.2023; 29(3): 779. CrossRef
Liver transplantation for malignant liver tumors
Richard X. Sousa Da Silva, Beat Muellhaupt, Philipp Dutkowski, Pierre-Alain Clavien
iLIVER.2022; 1(1): 3. CrossRef
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo
The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
Clinical and Molecular Hepatology.2022; 28(4): 876. CrossRef
How to Optimize the Care Cascade of Hepatitis C Virus Infection
Beom Kyung Kim
Gut and Liver.2022; 16(6): 809. CrossRef
Research trends analysis of chronic hepatitis C versus nonalcoholic fatty liver disease: A literature review text‐mining analysis of publications
Eyal Klang, Shelly Soffer, Lee Alper, Orit Shimon, Yiftach Barash, Yana Davidov, Mariya Likhter, Oranit Cohen‐Ezra, Gil Ben Yakov, Ziv Ben‐Ari
Health Science Reports.2022;[Epub] CrossRef
HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV
Kilian Weigand, Georg Peschel, Jonathan Grimm, Martina Müller, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler
Biomedicines.2022; 10(12): 3152. CrossRef

11,465 View
259 Download
21 Web of Science
Crossref

Original Articles

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B: Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim; Clin Mol Hepatol 2021;27(2):295-304.
Published online December 3, 2020; DOI: https://doi.org/10.3350/cmh.2020.0216

Background/Aims
The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase stringently defined by a low fibrosis-4 (FIB-4) index, compared to that in patients undergoing AVT.
Methods
Among 125 untreated patients that were hepatitis B e-antigen positive, hepatitis B virus-DNA >20,000 IU/mL, with normal alanine aminotransferase level from 2012 to 2018, those with a FIB-4 index of <1.45 were classified into the IT-group. The cumulative probability of HCC was estimated using Kaplan-Meier analysis. All patients were assessed until HCC development (intention-to-treat [ITT] analysis), whereas those suspected of experiencing CHB phase switch were assessed using the per-protocol (PP) and censored at the time of phase switch.
Results
The cumulative probability of HCC at 1-, 3-, and 5-years among the IT-group was zero, compared to AVT-treated patients with FIB-4 indices <1.45 during the same period: 0.2%, 0.6%, and 1.4%, respectively (P=0.264 for ITT and P=0.533 for PP). Among the initially screened 125 untreated patients, those with a FIB-4 index of ≥1.45 had a higher risk of HCC compared to the IT-group (P=0.005). Furthermore, among AVT-treated patients, those with a FIB-4 index of ≥1.45 had a higher risk of HCC compared to their counterpart (P<0.001).
Conclusions
The risk of HCC was negligible in the IT-group stringently defined by a low FIB-4 index. However, given that a higher HCC risk exists among untreated patients with higher FIB-4, appropriate criteria for AVT should be established.

Citations

Citations to this article as recorded by

AASLD IDSA Practice Guideline on treatment of chronic hepatitis B
Marc G. Ghany, Calvin Q. Pan, Anna S. Lok, Jordan J. Feld, Joseph K. Lim, Su H. Wang, Arthur Y. Kim, Amy S. Tang, Mindie H. Nguyen, Susanna Naggie, Mark S. Sulkowski, Rodriguez-Baez Norberto, Jacki Chen, M. Hassan Murad, Khaled S. Mohammad, Norah A. Terra
Hepatology.2026; 83(4): 974. CrossRef
Natural history of chronic hepatitis B in untreated adults without cirrhosis according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis
Daniela Yucuma, Arthur Rakover, Zakary Ismail Warsop, Yu Ri Im, Si Emma Chen, Rukmini Jagdish, Gibril Ndow, Maud Lemoine, Hailemichael Desalegn, Asgeir Johannessen, Hwai-I Yang, Yasuhito Tanaka, Roger Chou, Philippa Easterbrook, Yusuke Shimakawa
The Lancet Gastroenterology & Hepatology.2026; 11(5): 380. CrossRef
Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: A systematic review and meta-analysis
Jimmy Che-To Lai, Grace Lai-Hung Wong, Yee-Kit Tse, Vicki Wing-Ki Hui, Mandy Sze-Man Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Journal of Hepatology.2025; 82(6): 992. CrossRef
Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States
Kevin Pak, Ryan Sachar, Sammy Saab
Digestive Diseases and Sciences.2025; 70(4): 1547. CrossRef
Antiviral treatment response to nucleos(t)ide analogues in chronic hepatitis B patients with normal alanine aminotransferase levels: a retrospective multi-center study
Fei Cao, Jian Wang, Ye Xiong, Ying Zhang, Xinrong Zhang, Tao Fan, Li Zhu, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Yu Shi, Xiaomin Yan, Yuxin Chen, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang
Emerging Microbes & Infections.2025;[Epub] CrossRef
Gray zone of hepatitis B virus infection
Young-Suk Lim
Saudi Journal of Gastroenterology.2024; 30(2): 76. CrossRef
Treatment decisions based on HBV DNA
Young‐Suk Lim
Journal of Viral Hepatitis.2024; 31(S2): 36. CrossRef
HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx
Marc Ringelhan, Svenja Schuehle, Maarten van de Klundert, Elena Kotsiliti, Marie-Laure Plissonnier, Suzanne Faure-Dupuy, Tobias Riedl, Sebastian Lange, Karin Wisskirchen, Frank Thiele, Cho-Chin Cheng, Detian Yuan, Valentina Leone, Ronny Schmidt, Juliana H
JHEP Reports.2024; 6(10): 101128. CrossRef
Viral Load–Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B
Gi-Ae Kim, Young-Suk Lim, Seungbong Han, Gwang Hyeon Choi, Won-Mook Choi, Jonggi Choi, Dong Hyun Sinn, Yong-Han Paik, Jeong-Hoon Lee, Yun Bin Lee, Ju-Yeon Cho, Nae-Yun Heo, Man-Fung Yuen, Vincent Wai-Sun Wong, Stephen L. Chan, Hwai-I Yang, Chien-Jen Chen
Annals of Internal Medicine.2024; 177(10): 1308. CrossRef
Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: ‘Progress toward hepatitis B elimination in Canada’
Julian Hercun, Golasa Samadi Kochaksaraei, Simmone D'souza, Rachel Talavlikar, Jennifer Van Gennip, Carla Osiowy, Carla S Coffin, Harley Crowshoe
Canadian Liver Journal.2024; 7(3): 385. CrossRef
Management of antiviral treatment for chronic hepatitis B patients with high viral load
Ken Lin, Su-Wen Jiang, Ai-Rong Hu
World Chinese Journal of Digestology.2024; 32(9): 625. CrossRef
A nomogram based on HBeAg, AST, and age to predict non-minimal liver inflammation in CHB patients with ALT <80 U/L
Lu Zhang, Xiaoyue Bi, Xiaoxue Chen, Luxue Zhang, Qiqiu Xiong, Weihua Cao, Yanjie Lin, Liu Yang, Tingting Jiang, Wen Deng, Shiyu Wang, Shuling Wu, Ruyu Liu, Yuanjiao Gao, Ge Shen, Min Chang, Hongxiao Hao, Mengjiao Xu, Leiping Hu, Yao Lu, Minghui Li, Yao Xi
Frontiers in Immunology.2023;[Epub] CrossRef
Comparable outcomes between immune-tolerant and active phases in noncirrhotic chronic hepatitis B: a meta-analysis
Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Sang Hoon Ahn, Chai Hong Rim
Hepatology Communications.2023; 7(2): e0011. CrossRef
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
Moon Haeng Hur, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2023; 29(2): 363. CrossRef
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?
Joo Hyun Oh, Dong Hyun Sinn
Clinical and Molecular Hepatology.2023; 29(2): 367. CrossRef
Research Progress on the Need for Antiviral Therapy in Chronic HBV Infected Patients with Normal ALT
益帆胡
Advances in Clinical Medicine.2023; 13(04): 5360. CrossRef
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”
Chia-Ming Chu, Yun-Fan Liaw
Clinical and Molecular Hepatology.2023; 29(2): 510. CrossRef
Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication
Su-Wen Jiang, Xiang Lian, Ai-Rong Hu, Jia-Lin Lu, Zhe-Yun He, Xiao-Jun Shi, De-Dong Zhu, Zong-Yi Wang, Guan-Cheng Huang
World Journal of Gastroenterology.2023; 29(16): 2479. CrossRef
Management of Immune-Tolerant Patients with Chronic HBV Infection
Tai-Chung Tseng, Hung-Yao Lin, Jia-Horng Kao
Current Hepatology Reports.2023; 22(3): 130. CrossRef
Global importance of new treatment strategies to efforts to control hepatitis B virus
Carol Forbes, Louis Lavoie, Sacha Satram, Ling Shen, Vaidehi Thanawala, Andre Arizpe, Norah Terrault
Expert Review of Anti-infective Therapy.2023; 21(8): 847. CrossRef
HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
Soon Kyu Lee, Jung Hyun Kwon
Clinical and Molecular Hepatology.2023; 29(3): 825. CrossRef
Chronic Hepatitis B
Feng Su, Ira M. Jacobson
Clinics in Liver Disease.2023; 27(4): 791. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Early Treatment Consideration in Patients with Hepatitis B ‘e’ Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift?
Apostolos Koffas, Lung-Yi Mak, Upkar S. Gill, Patrick T. F. Kennedy
Viruses.2022; 14(5): 900. CrossRef
Genotypes Variation and Molecular Epidemiology Of The Hbv Chronic Liver Infection In The Local Population Of Pakistan: An Overview Of The Recent Literature
Bushra Tahreem, Ghadir Ali, Haroon Ahmad, Asim Shahzad, Muhammad Khurram, Nabiha Naeem, Aquib Nazar, Muhammad Haris, Hassan ., Shahrukh .
Pakistan BioMedical Journal.2022;[Epub] CrossRef
Surveillance for hepatocellular carcinoma: It is time to move forward
Bo Hyun Kim, Yuri Cho, Joong-Won Park
Clinical and Molecular Hepatology.2022; 28(4): 810. CrossRef
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact
Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong
Clinical and Molecular Hepatology.2021; 27(2): 273. CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Cancers.2021; 13(14): 3424. CrossRef

10,308 View
228 Download
28 Web of Science
Crossref

Viral hepatitis

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis: Po-Yao Hsu, Yu-Ju Wei, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Cheng-Ting Hsu, Tyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Meng-Hsuan Hsieh, Szu-Chia Chen, Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Jer-Ming Chang, Shang-Jyh Hwang, Wan-Long Chuang, Chung-Feng Huang, Yi-Wen Chiu, Ming-Lung Yu; Clin Mol Hepatol 2021;27(1):186-196.
Published online December 3, 2020; DOI: https://doi.org/10.3350/cmh.2020.0180

Background/Aims
Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis. Nevertheless, the complicated comedications and their potential drug-drug interactions (DDIs) with DAAs might limit clinical practice in this special population.
Methods
The number, class, and characteristics of comedications and their potential DDIs with five DAA regimens were analyzed among HCV-viremic patients from 23 hemodialysis centers in Taiwan.
Results
Of 2,015 hemodialysis patients screened in 2019, 169 patients seropositive for HCV RNA were enrolled (mean age, 65.6 years; median duration of hemodialysis, 5.8 years). All patients received at least one comedication (median number, 6; mean class number, 3.4). The most common comedication classes were ESRD-associated medications (94.1%), cardiovascular drugs (69.8%) and antidiabetic drugs (43.2%). ESRD-associated medications were excluded from DDI analysis. Sofosbuvir/velpatasvir/voxilaprevir had the highest frequency of potential contraindicated DDIs (red, 5.6%), followed by glecaprevir/pibrentasvir (4.0%), sofosbuvir/ledipasvir (1.3%), sofosbuvir/velpatasvir (1.3%), and elbasvir/grazoprevir (0.3%). For potentially significant DDIs (orange, requiring close monitoring or dose adjustments), sofosbuvir/velpatasvir/voxilaprevir had the highest frequency (19.9%), followed by sofosbuvir/ledipasvir (18.2%), glecaprevir/pibrentasvir (12.6%), sofosbuvir/velpatasvir (12.6%), and elbasvir/grazoprevir (7.3%). Overall, lipid-lowering agents were the most common comedication class with red-category DDIs to all DAA regimens (n=62), followed by cardiovascular agents (n=15), and central nervous system agents (n=10).
Conclusions
HCV-viremic patients on hemodialysis had a very high prevalence of comedications with a broad spectrum, which had varied DDIs with currently available DAA regimens. Elbasvir/grazoprevir had the fewest potential DDIs, and sofosbuvir/velpatasvir/voxilaprevir had the most potential DDIs.

Citations

Citations to this article as recorded by

Predictive value of osteoprotegerin and heart fatty acid binding protein as biomarkers for heart failure in chronic kidney disease patients on hemodialysis: A case-control study
Saddam Jaber Khudiar, Rayah Sulaiman Baban, Arif Sami Malik
Journal of Research in Pharmacy.2025; 29(2): 682. CrossRef
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Chien-Hung Chen, Chi-Ming Tai, Pin-Nan Cheng, Hsing-Tao Kuo, Kuo-Chih Tseng, Lein-Ray Mo, Ching-Chu Lo, Yi-Hsiang Huang, Han-Chieh Lin, Pei-Lun Lee, Ming-Jong Bai
Clinical and Molecular Hepatology.2025; 31(3): 899. CrossRef
Nationwide hepatitis C virus microelimination in uremic patients undergoing maintenance hemodialysis in Taiwan
Chung-Feng Huang, Po-Cheng Liang, Yu-Ju Wei, Chao-Chun Wu, Shi-Lun Wei, Li-Ju Lin, Pei-Chun Hsieh, Tsui-Hsia Hsu, Maggie Shu-Mei Hsu, Ya-Xin Luo, Hsi-Chieh Chen, Tsu-Yun Ho, Shao-Hsuan Lin, Chia-Ling Liu, Kuo-Pen Cheng, John W. Ward, Ming-Lung Yu
Journal of the Formosan Medical Association.2025; 124: S102. CrossRef
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Je
Clinical and Molecular Hepatology.2024; 30(3): 468. CrossRef
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review
Chen-Hua Liu, Yu-Ping Chang, Jia-Horng Kao
Expert Opinion on Pharmacotherapy.2024; 25(12): 1691. CrossRef
Comorbidities and Contraindicated Medications in Patients with Chronic Hepatitis C Infection in Japan: a Real-World Database Study
Takeya Tsutsumi, Hiroshi Yotsuyanagi
Kanzo.2024; 65(8): 368. CrossRef
Enhancing hepatitis C management in ESRD: Evaluating efficacy and safety of alternative antiviral regimens
Ume Aiman, Umer Bin Shahzad
Therapeutic Apheresis and Dialysis.2024; 28(6): 967. CrossRef
TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes
Ming-Lung Yu, Chih-Yuan Wang, Mei-Hsuan Lee, Horng-Yih Ou, Pin-Nan Cheng, Shih-Te Tu, Jee-Fu Huang, Jung-Fu Chen, Tsung-Hui Hu, Chih-Cheng Hsu, Jia-Horng Kao, Chien-Jen Chen, Han-Chieh Lin, Chien-Ning Huang
Journal of the Formosan Medical Association.2023; 122(3): 202. CrossRef
Drug–Drug Interactions With Over-The-Counter Medicines: Mind the Unprescribed
Oliver Scherf-Clavel
Therapeutic Drug Monitoring.2022; 44(2): 253. CrossRef
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5
Chen-Hua Liu, Jia-Horng Kao
Hepatology International.2022; 16(5): 1001. CrossRef
Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
Mario Enrico Canonico, Giuseppe Damiano Sanna, Roberta Siciliano, Fernando Scudiero, Giovanni Esposito, Guido Parodi
Frontiers in Pharmacology.2022;[Epub] CrossRef
Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid‐Reducing Agents
Tyler Shugg, Nicholas R. Powell, Patrick J. Marroum, Todd C. Skaar, Islam R. Younis
Clinical Pharmacology & Therapeutics.2022; 112(5): 1088. CrossRef
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study
Vicki Wing-Ki Hui, Christopher Langjun Au, Amy Shuk Man Lam, Terry Cheuk-Fung Yip, Yee-Kit Tse, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Grace Lai-Hung Wong
Hepatology International.2022; 16(6): 1318. CrossRef
HCV GT1b-patient With Alanine Aminotransferase Elevation and Sustained Virologic Response Achieved By grazoprevir/elbasvir Discontinuation
Hiroshi Takahashi, Tatsuo Kanda, Naoki Matsumoto, Taku Mizutani, Tomohiro Kaneko, Masayuki Honda, Yoichiro Yamana, Tomotaka Ishii, Mariko Kumagawa, Reina Sasaki, Ryota Masuzaki, Kazushige Nirei, Hiroaki Yamagami, Masahiro Ogawa, Shunichi Matsuoka, Mitsuhi
Future Virology.2021; 16(3): 161. CrossRef
Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy
Chung-Feng Huang, Yu-Ju Wei, Yu-Tse Wu, Yi-Wen Chiu, Ming-Lung Yu
Journal of Hepatology.2021; 75(4): 1006. CrossRef

12,570 View
235 Download
16 Web of Science
Crossref

Editorial

Viral hepatitis

More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis: Paul Kwo, Deepti Dronamraju; Clin Mol Hepatol 2020;26(4):489-491.
Published online September 24, 2020; DOI: https://doi.org/10.3350/cmh.2020.0228

Citations

Citations to this article as recorded by

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo
The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef

7,684 View
81 Download
1 Web of Science
Crossref

Original Articles

Viral hepatitis

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection: Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang; Clin Mol Hepatol 2019;25(4):400-407.
Published online May 28, 2019; DOI: https://doi.org/10.3350/cmh.2019.0006

Abstract
PDF

Background/Aims
In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The aim of the present analysis was to evaluate the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks in Korean patients who were enrolled in international clinical trial phase 3 studies.
Methods
This was a retrospective, integrated analysis of data from patients with HCV genotype (GT) 1b infection enrolled at Korean study sites in four EBR/GZR phase 3 clinical trials. Patients were treatment-naive or had previously failed interferon-based HCV therapy, and included those with human immunodeficiency virus coinfection or ChildPugh class A cirrhosis. All patients received EBR 50 mg/GZR 100 mg once daily for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after completion of therapy (SVR12, HCV RNA <15 IU/mL).
Results
SVR12 was achieved by 73 of 74 (98.6%) patients. No patients had virologic failure and one discontinued from the study after withdrawing consent. SVR12 rates were uniformly high across all patient subgroups. A total of 16 patients had nonstructural protein 5A resistance-associated substitutions at baseline (16/73, 22%), all of whom achieved SVR12. Adverse events (AEs) reported in >5% of patients were fatigue (6.8%), upper respiratory tract infection (5.4%), headache (5.4%), and nausea (5.4%). Thirteen patients (17.6%) reported drug-related AEs, two serious AEs occurred, and two patients discontinued treatment owing to an AEs.
Conclusions
In this retrospective analysis, EBR/GZR administered for 12 weeks was well-tolerated and highly effective in Korean patients with HCV GT1b infection.

Citations

Citations to this article as recorded by

The Incidence and Care Cascade of the Hepatitis C Virus in Korea
Young Eun Chon, Aejeong Jo, Eileen L. Yoon, Jonghyun Lee, Ho Gyun Shin, Min Jung Ko, Dae Won Jun
Gut and Liver.2023; 17(6): 926. CrossRef
Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis
Jieun Lee, Sang Bong Ahn, Sun Young Yim, Jihyun An, Dae Won Jun, Min Jung Ko, Dong Ah Park, Jeong‐Ju Yoo
Journal of Viral Hepatitis.2022; 29(7): 496. CrossRef
Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
Dorota Zarębska-Michaluk, Michał Brzdęk, Jerzy Jaroszewicz, Magdalena Tudrujek-Zdunek, Beata Lorenc, Jakub Klapaczyński, Włodzimierz Mazur, Adam Kazek, Marek Sitko, Hanna Berak, Justyna Janocha-Litwin, Dorota Dybowska, Łukasz Supronowicz, Rafał Krygier, J
World Journal of Gastroenterology.2022; 28(45): 6380. CrossRef
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
The Korean Journal of Internal Medicine.2021; 36(Suppl 1): S1. CrossRef
Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: the Increasing Impact of Alcohol
Jae Hyun Yoon, Chung Hwan Jun, Jeong Han Kim, Eileen L. Yoon, Byung Seok Kim, Jeong Eun Song, Ki Tae Suk, Moon Young Kim, Seong Hee Kang
Journal of Korean Medical Science.2021;[Epub] CrossRef
More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis
Paul Kwo, Deepti Dronamraju
Clinical and Molecular Hepatology.2020; 26(4): 489. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2020; 12(11): 3414. CrossRef

10,521 View
132 Download
9 Web of Science
Crossref

Viral hepatitis

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients: Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia Dietz, Martin Eisenacher, Helmut E. Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph Sarrazin, Grith Lykke Sorensen, Barbara Sitek, Thilo Bracht; Clin Mol Hepatol 2019;25(1):42-51.
Published online November 19, 2018; DOI: https://doi.org/10.3350/cmh.2018.0029

Background/Aims
An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs.
Methods
MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up visit (FU). Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed.
Results
MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R²=0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both).
Conclusions
Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.

Citations

Citations to this article as recorded by

Pathological Changes in Extracellular Matrix Composition Orchestrate the Fibrotic Feedback Loop Through Macrophage Activation in Dupuytren’s Contracture
Elizabeth Heinmäe, Kristina Mäemets-Allas, Katre Maasalu, Darja Vastšjonok, Mariliis Klaas
International Journal of Molecular Sciences.2025; 26(7): 3146. CrossRef
MFAP4 Deficiency Attenuates Liver Fibrosis by Regulating Hepatic Stellate Cell Fate Through Inhibition of the FAK/PI3K/NFκB Signaling Pathway
Linxiang Liu, Bimin Li, Yue Zhang, Yuan Nie, Wang Zhang, Peng Chen, Chenkai Huang, Xuan Zhu
Cellular and Molecular Gastroenterology and Hepatology.2025; 19(10): 101548. CrossRef
FGF7 promotes load-bearing tendon regeneration and suppresses fibrosis
Ruifu Lin, Junchao Luo, Hong Zhang, Chunmei Fan, Yue Hu, Ruojin Yan, Zetao Wang, Yang Fei, Chenqi Tang, Tianxi Huang, Tianshun Fang, Weiliang Shen, Sunbin Ling, Hongwei Ouyang, Xiao Chen, Zi Yin
Nature Communications.2025;[Epub] CrossRef
Role and new insights of microfibrillar‐associated protein 4 in fibrotic diseases
Long Zhu, Wenqun Gou, Lijia Ou, Binjie Liu, Manyi Liu, Hui Feng
APMIS.2024; 132(2): 55. CrossRef
Standardizing urethral stricture models in rats: a comprehensive study on histomorphologic and molecular approach
Osman Ergün, Muhammet Yusuf Tepebaşi, İbrahim Onaran, Sefa Alperen Öztürk, Mücahit Baltik, Pinar Aslan Koşar
International Urology and Nephrology.2024; 56(9): 2945. CrossRef
Predictors of liver fibrosis changes assessed by paired liver biopsies in chronic hepatitis C patients treated with direct-acting antivirals
Ming-Han Hsieh, Tzu-Yu Kao, Ting-Hui Hsieh, Chun-Chi Kao, Cheng-Yuan Peng, Hsueh-Chou Lai, Hsing-Hung Cheng, Mao-Wang Ho, Chih-Yu Chi, Jung-Ta Kao
Journal of Microbiology, Immunology and Infection.2024; 57(6): 840. CrossRef
Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities
Wei Chen, Yameng Sun, Shuyan Chen, Xiaodong Ge, Wen Zhang, Ning Zhang, Xiaoning Wu, Zhuolun Song, Hui Han, Romain Desert, Xuzhen Yan, Aiting Yang, Sukanta Das, Dipti Athavale, Natalia Nieto, Hong You
Hepatology.2023; 78(4): 1118. CrossRef
Microfibrillar-associated protein 4 in health and disease
Reine Kanaan, Myrna Medlej-Hashim, Rania Jounblat, Bartosz Pilecki, Grith L. Sorensen
Matrix Biology.2022; 111: 1. CrossRef
Molecular structure and function of microfibrillar‐associated proteins in skeletal and metabolic disorders and cancers
Sipin Zhu, Lin Ye, Samuel Bennett, Huazi Xu, Dengwei He, Jiake Xu
Journal of Cellular Physiology.2021; 236(1): 41. CrossRef
Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis
Emma Reungoat, Boyan Grigorov, Fabien Zoulim, Eve-Isabelle Pécheur
Cancers.2021; 13(9): 2270. CrossRef
Circadian, Week-to-Week, and Physical Exercise-Induced Variation of Serum Microfibrillar-Associated Protein 4
Susanne Gjørup Sækmose, René Holst, Tine Lottenburger, Henriette Ytting, Hans Jørgen Nielsen, Peter Junker, Anders Schlosser, Grith Lykke Sorensen
Biomarker Insights.2021;[Epub] CrossRef
Pathological investigations and correlation research of microfibrillar-associated protein 4 and tropoelastin in oral submucous fibrosis
Binjie Liu, Wenqun Gou, Hui Feng
BMC Oral Health.2021;[Epub] CrossRef
The fibrotic response of primary liver spheroids recapitulates in vivo hepatic stellate cell activation
Inge Mannaerts, Nathalie Eysackers, Elise Anne van Os, Stefaan Verhulst, Tiffany Roosens, Ayla Smout, Andreas Hierlemann, Olivier Frey, Sofia Batista Leite, Leo A. van Grunsven
Biomaterials.2020; 261: 120335. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2020; 12(11): 3414. CrossRef
Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment
Sun Hee Lee, Hyun Phil Shin, Joung Il Lee
Antiviral Chemistry and Chemotherapy.2020; 28: 204020662097483. CrossRef
Relationship between Microfibrillar-Associated Protein 4 Levels and Subclinical Myocardial Damage in Chronic Kidney Disease
Sonat Pınar Kara, Gülsüm Özkan, Demet Özkaramanlı Gür, Gaye Kübra Emeksiz, Ahsen Yılmaz, Nergiz Bayrakçı, Savaş Güzel
Cardiorenal Medicine.2020; 10(4): 257. CrossRef
Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C
Young Woo Eom, Soon Koo Baik
Clinical and Molecular Hepatology.2019; 25(1): 37. CrossRef

14,313 View
134 Download
17 Web of Science
Crossref

Viral hepatitis

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir: David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim; Clin Mol Hepatol 2019;25(3):283-293.
Published online November 13, 2018; DOI: https://doi.org/10.3350/cmh.2018.0054

Background/Aims
The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy.
Methods
A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited.
Results
Of the total study population, 146 (43.7%) patients had HS (CAP > 238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA<12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P=0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P=0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P=0.022).
Conclusions
CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.

Citations

Citations to this article as recorded by

Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis
Won-Mook Choi, Wai-Kay Seto
Hepatology.2026; 83(5): 1046. CrossRef
Impact of Non‐Alcoholic Fatty Liver Disease on the HBsAg Loss of Patients With Chronic Hepatitis B Treated in Pegylated Interferon Alpha
Chujing Li, Lihua Lin, Pei Zhou, Haiyi Cai, Songlian Liu, Xiaoyuan Chen, Aiqi Lu, Bo Li, Yaping Wang, Chuanghua Luo, Jianping Li, Yujuan Guan, Zhiwei Xie
Journal of Viral Hepatitis.2026;[Epub] CrossRef
The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B
Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu
Frontiers in Immunology.2026;[Epub] CrossRef
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection
Talal K Bhatti, Joseph K Lim
World Journal of Gastroenterology.2026;[Epub] CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S
Hepatology International.2025; 19(2): 261. CrossRef
Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
Clinical and Molecular Hepatology.2025; 31(Suppl): S182. CrossRef
The outcomes and mechanisms of chronic hepatitis B complicated by metabolic dysfunction-associated steatotic liver disease
Mao-Ping Li, Kai-Zhong Luo
Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 476. CrossRef
Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score
Yeun-Yoon Kim, Won Chang, Jeong Min Lee, Se Woo Kim, Jae Seok Bae, Jeongin Yoo, Sun Kyung Jeon, HeeSoo Kim, Young Hoon Kim, Jin-Young Choi, Eun Ju Cho, Yun Bin Lee, Sook-Hyang Jeong, Do Young Kim, Yunhee Choi, Jeong Hee Yoon
European Radiology.2025; 36(4): 2929. CrossRef
The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis
Georgia Zeng, Benjamin R. Holmes, Saleh A. Alqahtani, Upkar S. Gill, Patrick T. F. Kennedy
Frontiers in Gastroenterology.2024;[Epub] CrossRef
Effect of metabolic dysfunction‑associated fatty liver disease on the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A systematic review and meta‑analysis
Sixing Shen, Lingyan Pan
Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis
Shi-Yi Liu, Dian Wang, Jing Liu, Lu-Ping Yang, Gong-Ying Chen
World Journal of Hepatology.2024; 16(3): 465. CrossRef
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis
Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li
Journal of Viral Hepatitis.2024; 31(7): 372. CrossRef
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma
Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz
Heliyon.2024; 10(18): e37990. CrossRef
Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study
Fadi Abu Baker, Abdel-Rauf Zeina, Randa Taher, Saif Abu Mouch, Ariel Israel
Journal of Clinical Medicine.2024; 13(18): 5608. CrossRef
Effect of dyslipidemia on HBsAg clearance in nucleos(t)ide analogues-experienced chronic hepatitis B patients treated with peginterferon alfa
Kaimin Song, Lan Ren, Yunyun Qian, Huitong Wang, Zhixiang Guo, Huatang Zhang, Yijie Lin, Yijuan Zheng, Dawu Zeng, Yongjun Zhou, Zhijun Su, Xueping Yu
BMC Infectious Diseases.2024;[Epub] CrossRef
Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus
Hua-Dong Li, Ya-Nan Liu, Shuang Wu, Xu-Feng Quan, Xiao-Yan Wang, Tian-Dan Xiang, Shu-Meng Li, Ling Xu, Tong Wang, Hua Wang, Xin Zheng
World Journal of Hepatology.2024; 16(12): 1395. CrossRef
Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis
Xianhua Mao, Ka Shing Cheung, Chengzhi Peng, Lung‐Yi Mak, Ho Ming Cheng, James Fung, Noam Peleg, Howard H.‐W. Leung, Rajneesh Kumar, Jeong‐Hoon Lee, Amir Shlomai, Man‐Fung Yuen, Wai‐Kay Seto
Hepatology.2023; 77(5): 1735. CrossRef
Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
Lili Liu, Hong Li, Yang Zhang, Jing Zhang, Zhenhuan Cao
Heliyon.2023; 9(1): e13113. CrossRef
Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg‐positive chronic hepatitis B
Yanhua Tang, Rong Fan, Zhixian Lan, Qing Xie, Jiping Zhang, Xieer Liang, Hao Wang, Deming Tan, Jun Cheng, Shijun Chen, Qin Ning, Xuefan Bai, Min Xu, Xinyue Chen, Junqi Niu, Junping Shi, Hong Ren, Zhiliang Gao, Maorong Wang, Xiaoguang Dou, Jinlin Hou, Jian
Journal of Medical Virology.2023;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik
JHEP Reports.2023; 5(9): 100810. CrossRef
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis
Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vince
Clinical and Molecular Hepatology.2023; 29(3): 705. CrossRef
Predictors of treatment efficacy with nucleos(t)ide analogues for chronic hepatitis B
T. H. Nguyen, L. Yu. Ilchenko, L. I. Melnikova, K. K. Kyuregyan, I. V. Gordeychuk, N. L. Bondarenko
Experimental and Clinical Gastroenterology.2023; (4): 77. CrossRef
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeongjun Song
Nutrients.2023; 15(18): 3970. CrossRef
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver
Mi Na Kim, Kyungdo Han, Juhwan Yoo, Seong Gyu Hwang, Sang Hoon Ahn
Alimentary Pharmacology & Therapeutics.2022; 55(1): 97. CrossRef
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia
BMC Cancer.2022;[Epub] CrossRef
One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B
Yi-Cheng Chen, Chao-Wei Hsu, Rong-Nan Chien, Dar-In Tai
Medicine.2022; 101(25): e29269. CrossRef
Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease
Xin Tong, Yu Song, Shengxia Yin, Jian Wang, Rui Huang, Chao Wu, Junping Shi, Jie Li
Chinese Medical Journal.2022; 135(14): 1653. CrossRef
Bioelectrical Impedance Analysis Can Be an Effective Tool for Screening Fatty Liver in Patients with Suspected Liver Disease
Jin Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Healthcare.2022; 10(11): 2268. CrossRef
Interaction and Possible Mechanism between Non-Alcoholic Fatty Liver Disease and Chronic Hepatitis B
博诗陈
Advances in Clinical Medicine.2022; 12(11): 10453. CrossRef
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim
Journal of Gastroenterology and Hepatology.2021; 36(5): 1317. CrossRef
Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy
Jin Won Chang, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Gut and Liver.2021; 15(1): 117. CrossRef
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Ho Soo Chun, Sojeong Park, Minjong Lee, Yuri Cho, Ha Sung Kim, A Reum Choe, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Cancers.2021; 13(14): 3424. CrossRef
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
Joo Hyun Oh, Hye Won Lee, Dong Hyun Sinn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik
Hepatology International.2021; 15(4): 892. CrossRef
Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment
Xiu-Juan Chang, Yi-Wen Shi, Jing Wang, Hua-Bao Liu, Yan Chen, Xiao-Ning Zhu, Yong-Ping Chen, Zu-Jiang Yu, Qing-Hua Shang, Lin Tan, Qin Li, Li Jiang, Guang-Ming Xiao, Liang Chen, Wei Lu, Xiao-Yu Hu, Qing-Hua Long, Lin-Jing An, Zi-Yuan Zou, Vincent Wai-Sun
Hepatobiliary & Pancreatic Diseases International.2021; 20(5): 416. CrossRef
No influence of hepatic steatosis on the 3‐year outcomes of patients with quiescent chronic hepatitis B
Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Journal of Viral Hepatitis.2021; 28(11): 1545. CrossRef
Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model
Yuanqin Duan, Zhiwei Chen, Hu Li, Wei Shen, Yi Zeng, Mingli Peng, Peng Hu
Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Journal of Korean Medical Science.2020;[Epub] CrossRef
Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
Yi-Cheng Chen, Wen-Juei Jeng, Chao-Wei Hsu, Chun-Yen Lin
BMC Gastroenterology.2020;[Epub] CrossRef
Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir
Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park
Clinical and Molecular Hepatology.2020; 26(3): 364. CrossRef
Letter: risk of hepatocellular carcinoma in immune‐tolerant phase of chronic hepatitis B—authors’ reply
Han Ah Lee, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2020; 52(5): 913. CrossRef
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau, Aysha Aslam
Microorganisms.2020; 8(10): 1526. CrossRef
Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune‐tolerant phase—authors' reply
Han Ah Lee, Seung Up Kim
Alimentary Pharmacology & Therapeutics.2020; 52(6): 1094. CrossRef
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?
Jung Hwan Yu, Jin-Woo Lee
Clinical and Molecular Hepatology.2019; 25(3): 280. CrossRef
Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease
Seung Up Kim, Mi Young Jeon, Tae Seop Lim
The Korean Journal of Gastroenterology.2019; 74(6): 341. CrossRef

15,457 View
263 Download
43 Web of Science
Crossref

Viral hepatitis

Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them: Kwang Il Seo, Si Hyun Bae, Pil Soo Sung, Chung-Hwa Park, Hae Lim Lee, Hee Yeon Kim, Hye Ji Kim, Bo Hyun Jang, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi, In-Yang Park, Juyoung Lee, Hyun Seung Lee, Sa-Jin Kim, Jung Hyun Kwon, U Im Chang, Chang Wook Kim, Se Hyun Jo, Young Lee, Fisseha Tekle, Jong-Hyun Kim; Clin Mol Hepatol 2018;24(4):374-383.
Published online June 26, 2018; DOI: https://doi.org/10.3350/cmh.2017.0082

Abstract
PDF

Background/Aims
There have been numerous efforts to reduce mother-to-child transmission (MTCT) of hepatitis B virus (HBV) with antiviral agents during pregnancy. However, there are limited data regarding the outcomes of pregnant women after delivery. This study was performed to evaluate the efficacy of antiviral agents in preventing MTCT of HBV and maternal long-term outcomes.
Methods
The HBV-infected pregnant women treated with antiviral agents to prevent MTCT were retrospectively reviewed. Forty-one pregnant women who received telbivudine or tenofovir during late pregnancy (28-34 week) were analyzed. Hepatitis B virus surface antibody (HBsAb) positivity was tested in 43 infants after 7 months of birth. Eleven mothers were followed >1 year after delivery.
Results
The mean HBV DNA titer before antiviral therapy was 8.67 (6.60–9.49) log copies/mL, and the median age at delivery was 32 years (range, 22–40). Eleven patients were treated with tenofovir and 30 with telbivudine. The median duration was 57 days (range, 23–100), and the median HBV DNA titer at birth was 5.06 log copies/mL (range, 2.06–6.50). Antiviral treatments were associated with significant HBV DNA reduction (P<0.001). Among 43 infants (two cases of twins), HBsAb was not detected in two, subsequently confirmed to have HBV infection. Biochemical flare was observed in two of 11 mothers followed >12 months, and an antiviral agent was administered.
Conclusions
Antiviral treatment during late pregnancy effectively reduced MTCT. Long-term follow-up should be required in such cases. In addition, given that maternal biochemical flare occurred in 18% of mothers, re-administration of antiviral agents might be required.

12,736 View
340 Download
1 Web of Science

Viral hepatitis

Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling: Pil Soo Sung, Eun Byul Lee, Dong Jun Park, Angelo Lozada, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon; Clin Mol Hepatol 2018;24(3):302-310.
Published online March 12, 2018; DOI: https://doi.org/10.3350/cmh.2017.0074

Abstract
PDF

Background/Aims
Hepatitis C virus (HCV) replicates in the peripheral blood mononuclear cells (PBMCs), leading to the production of type I interferons (IFNs). It is well known that the gene expression profile of PBMC is similar to that of the liver. The present study explored the dynamic gene expression profile of PBMCs collected from HCV-infected patients undergoing direct-acting antiviral (DAA) therapy.
Methods
A prospective cohort comprising 27 patients under DAA therapy was formed. Expression level of IFN-β and its downstream interferon-stimulated genes (ISGs) was measured in PBMCs before and after DAA treatment. Furthermore, immunoblotting was performed to identify the signaling molecules involved in the expression of ISGs.
Results
The pretreatment expression level of interferon-induced protein 44 (IFI44) and C-X-C motif chemokine ligand 10 (CXCL10) correlated with the pretreatment expression level of IFN-β. After DAA treatment, a significant decrease in the expression levels of IFN-β, IFI44, and CXCL10 was observed in the PBMCs. Furthermore, the pretreatment expression level of IFN-β and ISGs correlated with the level of signal transducer and activator of transcription 1 (STAT1) phosphorylation, and DAA treatment abrogated STAT1 phosphorylation.
Conclusions
Pretreatment activation of IFN-β response is rapidly normalized after DAA treatment. The present study suggests that the decreased type I IFN response by the clearance of HCV might contribute to DAA-induced alleviation of extrahepatic manifestation of chronic HCV infection.

Citations

Citations to this article as recorded by

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(3): 326. CrossRef
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’Onghia, Antonio Ottobrelli, Silvia Martini, Christian Bracco, Luigi Maria Fenoglio, Mauro
Viruses.2024; 16(12): 1899. CrossRef
Transcriptional responses define dysregulated immune activation in Hepatitis C (HCV)-naïve recipients of HCV-infected donor kidneys
Julie M. Steinbrink, Cameron Miller, Rachel A. Myers, Scott Sanoff, Anna Mazur, Thomas W. Burke, Jennifer Byrns, Annette M. Jackson, Xunrong Luo, Micah T. McClain, Jason T. Blackard
PLOS ONE.2023; 18(1): e0280602. CrossRef
DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people
Samaa T. Gobran, Amélie Pagliuzza, Omar Khedr, Augustine Fert, Nicolas Chomont, Julie Bruneau, Marina B. Klein, Petronela Ancuta, Naglaa H. Shoukry, Viviana Simon
Journal of Virology.2023;[Epub] CrossRef
Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virus–Sustained Virological Response Patients
Minh Phuong Dong, Le Thi Thanh Thuy, Dinh Viet Hoang, Hoang Hai, Truong Huu Hoang, Misako Sato-Matsubara, Vu Ngoc Hieu, Atsuko Daikoku, Ngo Vinh Hanh, Hayato Urushima, Ninh Quoc Dat, Sawako Uchida-Kobayashi, Masaru Enomoto, Naoko Ohtani, Akihiro Tamori, N
The American Journal of Pathology.2022; 192(10): 1379. CrossRef
Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
Pil Soo Sung, Eui-Cheol Shin
Journal of Clinical Medicine.2021; 10(2): 221. CrossRef
Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma
Xinhe Zhang, Lin Guan, Haoyu Tian, Zilu Zeng, Jiayu Chen, Die Huang, Ji Sun, Jiaqi Guo, Huipeng Cui, Yiling Li
Frontiers in Oncology.2021;[Epub] CrossRef
HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
Óscar Brochado-Kith, Isidoro Martínez, Juan Berenguer, Juan González-García, Sergio Salgüero, Daniel Sepúlveda-Crespo, Cristina Díez, Víctor Hontañón, Luis Ibañez-Samaniego, Leire Pérez-Latorre, Amanda Fernández-Rodríguez, María Ángeles Jiménez-Sousa, Sal
Frontiers in Immunology.2021;[Epub] CrossRef
A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection
Samaa T. Gobran, Petronela Ancuta, Naglaa H. Shoukry
Frontiers in Immunology.2021;[Epub] CrossRef
Hepatitis C Virus Cure in Human Immunodeficiency Virus Coinfection Dampens Inflammation and Improves Cognition Through Multiple Mechanisms
Bing Sun, Linda Abadjian, Alexander Monto, Heather Freasier, Lynn Pulliam
The Journal of Infectious Diseases.2020; 222(3): 396. CrossRef
Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals
Pil Soo Sung, Eui-Cheol Shin
International Journal of Molecular Sciences.2020; 21(7): 2583. CrossRef
Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment

Srikanta Dash, Yucel Aydin, Kyle E Widmer, Leela Nayak
Journal of Hepatocellular Carcinoma.2020; Volume 7: 45. CrossRef
EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1
Dong Jun Park, Pil Soo Sung, Jung-Hee Kim, Gil Won Lee, Jeong Won Jang, Eun Sun Jung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Journal for ImmunoTherapy of Cancer.2020; 8(1): e000301. CrossRef
Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
Luca Rinaldi, Riccardo Nevola, Gianluigi Franci, Alessandro Perrella, Giusy Corvino, Aldo Marrone, Massimiliano Berretta, Maria Vittoria Morone, Marilena Galdiero, Mauro Giordano, Luigi Elio Adinolfi, Ferdinando Carlo Sasso
Cancers.2020; 12(6): 1351. CrossRef
microRNA-99a Restricts Replication of Hepatitis C Virus by Targeting mTOR and De Novo Lipogenesis
Eun Byul Lee, Pil Soo Sung, Jung-Hee Kim, Dong Jun Park, Wonhee Hur, Seung Kew Yoon
Viruses.2020; 12(7): 696. CrossRef
Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?
Silvia Martina Ferrari, Poupak Fallahi, Ilaria Ruffilli, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Armando Patrizio, Valeria Mazzi, Michele Colaci, Dilia Giuggioli, Clodoveo Ferri, Alessandro Antonelli
Journal of Immunology Research.2019; 2019: 1. CrossRef
APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
Tatsuo Kanda, George K. K. Lau, Lai Wei, Mitsuhiko Moriyama, Ming-Lung Yu, Wang-Long Chuang, Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Jose Sollano, Manoj Kumar, Ankur Jindal, Barjesh Chander Sharma, Saeed S. Hamid, A. Kadir Dokmeci, Mamun-Al-Ma
Hepatology International.2019; 13(6): 649. CrossRef
Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response
Reina Sasaki, Tatsuo Kanda, Naoya Kato, Osamu Yokosuka, Mitsuhiko Moriyama
World Journal of Hepatology.2018; 10(12): 898. CrossRef
Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications
Pil Soo Sung, Jeong Won Jang
International Journal of Molecular Sciences.2018; 19(11): 3648. CrossRef

13,986 View
189 Download
19 Web of Science
Crossref

Current status of Liver diseases in Korea: Hepatitis B: Hee Bok Chae , Jong Hyun Kim , Ja Kyung Kim , Hyung Joon Yim; Korean J Hepatol 2009;15(60):13-24.
Published online December 31, 2009; DOI: https://doi.org/10.3350/kjhep.2009.15.S6.S13

Citations

Citations to this article as recorded by

한국 B형간염 코호트의 임상적 특성 및 치료 효과 분석
태용 김, 재승 이, 외욱 정, 정규 이, 승미 최, 상미 류, 민진 고, 정연 김
Public Health Weekly Report.2026; 19(13): 539. CrossRef
Understanding Hepatitis B Knowledge, Attitudes, and Stigma in the Korean Community in Australia
Youngnam Baek, Robyn Horwitz, Loren Brener, Sylvester Okeke, Tim Broady, Carla Treloar, Elena Cama
Journal of Racial and Ethnic Health Disparities.2025;[Epub] CrossRef
Vitamin K: Calcium Metabolism Modulator for Menopausal Women
Tae-Hee Kim, Hayeon Kim, Hae Hyeog Lee, Jae Hong Sang
Journal of Menopausal Medicine.2024; 30(3): 152. CrossRef
A Study on the Trend of Changes in the Positive Rate of Hepatitis B Surface Antigens and Antibodies over the Last 9 Years in One Health Care Center
Kang-Sil Lee, Sang-Ha Kim, Young-Bin Yu, Young-Kwon Kim
Biomedical Science Letters.2023; 29(4): 314. CrossRef
Long-term outcomes of primary total knee arthroplasty in patients with hepatitis B virus infection
Ji-Hoon Baek, Su C. Lee, Suengryol Ryu, Jin-Woo Kim, Chang H. Nam
Bone & Joint Open.2022; 3(6): 470. CrossRef
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clinical and Molecular Hepatology.2020; 26(4): 411. CrossRef
Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial
Hyung Joon Yim, Won Kim, Sang Hoon Ahn, Jin Mo Yang, Jae Young Jang, Yong Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Soon Ho Um, Joo Hyun Sohn, Jin Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Ki
American Journal of Gastroenterology.2020; 115(8): 1217. CrossRef
Alterations of the Gut Microbiome in Chronic Hepatitis B Virus Infection Associated with Alanine Aminotransferase Level
Yeojun Yun, Yoosoo Chang, Han-Na Kim, Seungho Ryu, Min-Jung Kwon, Yong Kyun Cho, Hyung-Lae Kim, Hae Suk Cheong, Eun-Jeong Joo
Journal of Clinical Medicine.2019; 8(2): 173. CrossRef
Updated Treatment of Chronic Hepatitis B
Eileen L. Yoon, Hyung Joon Yim
The Korean Journal of Medicine.2019; 94(3): 252. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
Seroepidemiology of Hepatitis Viruses and Hepatitis B Genotypes of Female Marriage Immigrants in Korea
Jae-Cheol Kwon, Hye Young Chang, Oh Young Kwon, Ji Hoon Park, In Soo Oh, Hyung Joon Kim, Jun Hyung Lee, Ha-Jung Roh, Hyun Woong Lee
Yonsei Medical Journal.2018; 59(9): 1072. CrossRef
Negative Association of Hepatitis B Virus With Hearing Impairment
SKM Azizul Islam, Jin Wook Chung, Young-Sil Lee, HoChan Cho, Seong-Su Moon
American Journal of Audiology.2018; 27(3): 324. CrossRef
Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B
Chang Wook Kim, Chang Seop Kim, Hee Yeon Kim, Chang Don Lee, Kyungha Yu, Cyril Llamoso, Heon Ju Lee
The Korean Journal of Internal Medicine.2018; 33(1): 91. CrossRef
An expert consensus for the management of chronic hepatitis B in Asian Americans
M. J. Tong, C. Q. Pan, S.‐H. B. Han, D. S.‐K. Lu, S. Raman, K.‐Q. Hu, J. K. Lim, H. W. Hann, A. D. Min
Alimentary Pharmacology & Therapeutics.2018; 47(8): 1181. CrossRef
Therapeutic Efficacy of Lamivudine in Children and Adolescents with Chronic Hepatitis B
Yujung Choi, Kil Seoung Bae, Ki Hwan Kim, Dae Kyun Koh, Jong-Hyun Kim
Pediatric Infection & Vaccine.2018; 25(2): 72. CrossRef
How can we improve the performance of Model for End‐Stage Liver Disease sodium score in patients with hepatitis B virus‐related decompensated liver cirrhosis commencing antiviral treatment?
Tae Hyung Kim, Dae Hoe Ku, Soon Ho Um, Han Ah Lee, Seung Woon Park, Jung Mi Chang, Sun Young Yim, Sang Jun Suh, Young Kul Jung, Yeon Seok Seo, Ji Hoon Kim, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Hyonggin Ahn
Journal of Gastroenterology and Hepatology.2018; 33(9): 1641. CrossRef
The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B
Jae Min Lee, Yeon Seok Seo, Tae Hyung Kim, Jem Ma Ahn, Sun Young Yim, Seung Up Kim, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Hong Sik Lee, Kwan Soo Byun, Soon Ho Um, Chang Duck Kim, Ho Sang Ryu
Journal of Gastroenterology and Hepatology.2017; 32(1): 208. CrossRef
Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B
Kwan Sik Lee, Young-Oh Kweon, Soon-Ho Um, Byung-Ho Kim, Young Suk Lim, Seung Woon Paik, Jeong Heo, Heon-Ju Lee, Dong Joon Kim, Tae Hun Kim, Young-Sok Lee, Kwan Soo Byun, Daeghon Kim, Myung Seok Lee, Kyungha Yu, Dong Jin Suh
Clinical and Molecular Hepatology.2017; 23(4): 331. CrossRef
A Case Report of the Efficacy of Saenggan-tang-gagam in the Treatment of a Patient with Chronic Hepatitis B Who Showed Conversion of the Immune-Tolerant Phase to Immune-Clearance Phase during Hospitalization for Intracerebral Hemorrhage
Jung-han Bae, Ha-yeon Kim, Seong-hee Joo, Eun-gyeong Jang, Jang-hoon Lee, Young-chul Kim
The Journal of Internal Korean Medicine.2017; 38(2): 164. CrossRef
Association of Hepatitis B Virus Infection and Psoriasis
Hyun-Yi Suh, Yong-Bum Yoon, Ji-Young Ahn, Mi-Youn Park, Jai-Il Youn
Annals of Dermatology.2017; 29(6): 822. CrossRef
The Economic Burden of Hepatitis A, B, and C in South Korea
Changwoo Shon, Hyung-Yun Choi, Jae-Jun Shim, So-Youn Park, Kyung Suk Lee, Seok-Jun Yoon, In-Hwan Oh
Japanese Journal of Infectious Diseases.2016; 69(1): 18. CrossRef
KASL clinical practice guidelines: management of chronic hepatitis B

Clinical and Molecular Hepatology.2016; 22(1): 18. CrossRef
Association of HLA-DP variants with the responsiveness to Hepatitis B virus vaccination in Korean Infants
Eun Youn Roh, Jong Hyun Yoon, Ji Won In, Nuri Lee, Sue Shin, Eun Young Song
Vaccine.2016; 34(23): 2602. CrossRef
A 96‐week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy
Sang Hoon Ahn, Jeong Heo, Jun Yong Park, Hyun Young Woo, Heon Ju Lee, Won Young Tak, Soon Ho Um, Ki Tae Yoon, Soo Young Park, Chang Wook Kim, Hyung Hoi Kim, Kwang‐Hyub Han, Mong Cho
Journal of Gastroenterology and Hepatology.2016; 31(4): 865. CrossRef
Age-Period-Cohort Analysis of Liver Cancer Mortality in Korea
Jihwan Park, Yon Ho Jee
Asian Pacific Journal of Cancer Prevention.2016; 16(18): 8589. CrossRef
Prevalence of Hepatitis B Virus and HIV Co-infection in Korea
Hyun-Ho Lee, Hae-Guen Hong, Jong-Seong Son, Sun-Mok Kwon, Bu-Geon Lim, Kang-Bum Lee, Gu-Hwan Kim
Journal of Bacteriology and Virology.2016; 46(4): 283. CrossRef
Hepatitis B Virus-Related Glomerulonephritis: Not a Predominant Cause of Proteinuria in Korean Patients with Chronic Hepatitis B
Jeong-Ju Yoo, Jeong-Hoon Lee, Jung-Hwan Yoon, Minjong Lee, Dong Hyeon Lee, Yuri Cho, Eun Sun Jang, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Hyo-Suk Lee
Gastroenterology Research and Practice.2015; 2015: 1. CrossRef
Efficacy of telbivudine compared with entecavir in hepatitis B virus‐related cirrhosis: 2 year follow‐up data
Hae Rim Kim, Hyung Joon Yim, Seonghee Kang, Sang Jun Suh, Seung Young Kim, Jong Jin Hyun, Ja Seol Koo, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Sang Woo Lee, Kwan Soo Byun, Soon Ho Um
Liver International.2015; 35(3): 860. CrossRef
Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels
Junggyu Lee, Dong Hyun Sinn, Jung Hee Kim, Geum-Youn Gwak, Hye Seung Kim, Sin-Ho Jung, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Seung Woon Paik
Journal of Korean Medical Science.2015; 30(11): 1618. CrossRef
Fighting Hepatitis B in North Korea: Feasibility of a Bi-modal Prevention Strategy
Markus Unnewehr, August Stich
Journal of Korean Medical Science.2015; 30(11): 1584. CrossRef
Analysis of HBV genotype, drug resistant mutations, and pre‐core/basal core promoter mutations in Korean patients with acute hepatitis B
Jong Ho Lee, Sun Pyo Hong, Eun Sun Jang, Sang Jong Park, Seong Gyu Hwang, Sook‐Kyoung Kang, Sook‐Hyang Jeong
Journal of Medical Virology.2015; 87(6): 993. CrossRef
Clinical Characteristics of Defectors from North Korea Visiting a Single Tertiary Hospital in South Korea
Sun Young Ann, Sung Hyeok Ryou, Suk Bae Kim
Korean Journal of Medicine.2015; 89(1): 54. CrossRef
Blood Lead Levels and Cause-Specific Mortality of Inorganic Lead-Exposed Workers in South Korea
Min-Gi Kim, Jae-Hong Ryoo, Se-Jin Chang, Chun-Bae Kim, Jong-Ku Park, Sang-Baek Koh, Yeon-Soon Ahn, Max Costa
PLOS ONE.2015; 10(10): e0140360. CrossRef
Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas
Sejong Chun, Su Yeon Rhie, Chang-Seok Ki, Jee Eun Kim, Hyung-Doo Park
Annals of Hepatology.2015; 14(6): 881. CrossRef
Iron deficient erythropoiesis might play key role in development of anemia in cancer patients
Silvia Park, Chul Won Jung, Kihyun Kim, Seok Jin Kim, Won Seog Kim, Jun Ho Jang
Oncotarget.2015; 6(40): 42803. CrossRef
Prevalence of and Factors Influencing Impaired Glucose Tolerance Among Hepatitis B Carriers
Boyoung Park, Kyu-Won Jung, Chang-Mo Oh, Kui Son Choi, Mina Suh, Jae Kwan Jun
Medicine.2014; 93(20): e91. CrossRef
The association between underweight and the development of albuminuria is different between sexes in relatively healthy Korean subjects
C. M. Jang, Y. Y. Hyun, K. B. Lee, H. Kim
Nephrology Dialysis Transplantation.2014; 29(11): 2106. CrossRef
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clinical and Molecular Hepatology.2014; 20(3): 274. CrossRef
Association of HLA alleles with the responsiveness to hepatitis B virus vaccination in Korean infants
Jong Hyun Yoon, Sue Shin, Ji won In, Ju Young Chang, Eun Young Song, Eun Youn Roh
Vaccine.2014; 32(43): 5638. CrossRef
Role of the PNPLA3 I148M Polymorphism in Nonalcoholic Fatty Liver Disease and Fibrosis in Korea
Sang Soo Lee, Young-Sang Byoun, Sook-Hyang Jeong, Byung Hyun Woo, Eun Sun Jang, Jin-Wook Kim, Hyun Young Kim
Digestive Diseases and Sciences.2014; 59(12): 2967. CrossRef
Correlation Between Risk of Hepatitis B Virus Recurrence and Tissue Expression of Covalently Closed Circular DNA in Living Donor Liver Transplant Recipients Treated With High-dose Hepatitis B Immunoglobulin
G.-W. Song, C.-S. Ahn, S.-G. Lee, S. Hwang, K.-H. Kim, D.-B. Moon, T.-Y. Ha, D.-H. Jung, G.-C. Park, S.-H. Kang, B.-H. Jung, N. Kim
Transplantation Proceedings.2014; 46(10): 3548. CrossRef
Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort
Dong Hyun Sinn, Geum-Youn Gwak, Juhee Cho, Seung Woon Paik, Byung Chul Yoo, Pierre Roques
PLoS ONE.2014; 9(11): e112184. CrossRef
Determinants of suboptimal hepatitis B vaccine uptake among men in the Republic of Korea: where should our efforts be focused: results from cross-sectional study
Boyoung Park, Kui Son Choi, Hoo-Yeon Lee, Min-Son Kwak, Jae Kwan Jun, Eun-Cheol Park
BMC Infectious Diseases.2013;[Epub] CrossRef
Clinical Characteristics and Treatment of Patients with IgA Nephropathy and Hepatitis B Surface Antigen
In O Sun, Yu Ah Hong, Hoon Suk Park, Sun Ryoung Choi, Byung Ha Chung, Cheol Whee Park, Chul Woo Yang, Yong Soo Kim, Bum Soon Choi
Renal Failure.2013; 35(4): 446. CrossRef
HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data
Jeong Han Kim, Yun Jung Choi, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clinical and Molecular Hepatology.2013; 19(4): 409. CrossRef
Recent trends in hepatitis B virus infection in the general Korean population
Hyuck Kim, A Ri Shin, Hoe Hoon Chung, Min Kyoung Kim, Ji Sung Lee, Jae-Jun Shim, Byung-Ho Kim
The Korean Journal of Internal Medicine.2013; 28(4): 413. CrossRef
The Roles of Immune Regulatory Factors FoxP3, PD-1, and CTLA-4 in Chronic Viral Infection
Hyosun Cho
The Korean Journal of Microbiology.2013; 49(3): 221. CrossRef
Viral Hepatitis and Liver Cancer in Korea: an Epidemiological Perspective
Yohwan Yeo, Jin Gwack, Seokin Kang, Boyeon Koo, Sun Jae Jung, Prakash Dhamala, Kwang-Pil Ko, Young-Khi Lim, Keun-Young Yoo
Asian Pacific Journal of Cancer Prevention.2013; 14(11): 6227. CrossRef
Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti‐HBs
Byung Seok Lee, Yong Kyun Cho, Sook‐Hyang Jeong, Joon Hyeok Lee, Don Lee, Neung Hwa Park, Moran Ki
Journal of Medical Virology.2013; 85(8): 1327. CrossRef
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
Jeong Han Kim, Soon Young Ko, Won Hyeok Choe, So Young Kwon, Chang Hong Lee
Clinical and Molecular Hepatology.2013; 19(3): 273. CrossRef
Work-related infectious diseases among Korean workers compensated under the Industrial Accident Compensation Insurance Law, 2006–2011
Jun-Pyo Myong, Yeon-Soon Ahn, Hyoung-Ryoul Kim, Youn Jeong Kim, Chung Yill Park, Jung-Wan Koo
International Journal of Occupational and Environmental Health.2013; 19(4): 344. CrossRef
Prevention of Viral Hepatitis and Vaccination
Yoo-Kyung Cho, Byung-Cheol Song
Korean Journal of Medicine.2012; 82(2): 123. CrossRef
KASL Clinical Practice Guidelines: Management of chronic hepatitis B

Clinical and Molecular Hepatology.2012; 18(2): 109. CrossRef
Prevalence of rheumatoid factor and parameters associated with rheumatoid factor positivity in Korean health screening subjects and subjects with hepatitis B surface antigen
Choong-Nam Shim, Ji-Won Hwang, Jaejoon Lee, Eun-Mi Koh, Hoon-Suk Cha, Joong Kyong Ahn
Modern Rheumatology.2012; 22(6): 885. CrossRef
Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study
Sang Hoon Park, Choong Kee Park, Jin Woo Lee, Young Seok Kim, Sook-Hyang Jeong, Yun Soo im, Ju Hyun Kim, Seong Gyu Hwang, Kyu Sung Rim, Hyung Joon Yim, Jae Youn Cheong, Sung Won Cho, June Sung Lee, Young Min Park, Jeong Won Jang Chun Kyon Lee, Joo Hyun Sh
Gut and Liver.2012; 6(1): 98. CrossRef
Prognosis of hepatitis B‐related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents
Chang Ha Kim, Soon Ho Um, Yeon Seok Seo, Jin Yong Jung, Jin Dong Kim, Hyung Joon Yim, Bora Keum, Yong Sik Kim, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim, Ho Sang Ryu
Journal of Gastroenterology and Hepatology.2012; 27(10): 1589. CrossRef
The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study
Moon Seok Choi, Dong Hyun Sinn, Su-A Kim, Yil Seob Lee, Won Choi, Seung Woon Paik
Gut and Liver.2012; 6(2): 241. CrossRef
Socioeconomic inequalities in completion of hepatitis B vaccine series among Korean women: Results from a nationwide interview survey
Boyoung Park, Kui Son Choi, Hoo-Yeon Lee, Jae Kwan Jun, Eun-Cheol Park
Vaccine.2012; 30(40): 5844. CrossRef
Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B
Jeong Han Kim, So Young Kwon, Young Sok Lee, Joon Hyoek Lee, Yil–Seob Lee, Chang Hong Lee
Clinical Gastroenterology and Hepatology.2012; 10(3): 291. CrossRef
Serum Selenium Levels in Korean Hepatoma Patients
In-Wook Kim, Su-Mi Bae, Yong-Wan Kim, Hai-Bo Liu, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Pankaj Kumar Chaturvedi, Gantumur Battogtokh, Woong Shick Ahn
Biological Trace Element Research.2012; 148(1): 25. CrossRef
Differences in characteristics between healthcare-associated and community-acquired infection in community-onset Klebsiella pneumoniae bloodstream infection in Korea
Younghee Jung, Myung Jin Lee, Hye-Yun Sin, Nak-Hyun Kim, Jeong-Hwan Hwang, Jinyong Park, Pyoeng Gyun Choe, Wan Beom Park, Eu Suk Kim, Sang-Won Park, Kyoung Un Park, Hong Bin Kim, Nam-Joong Kim, Eui-Chong Kim, Kyoung-Ho Song, Myoung-don Oh
BMC Infectious Diseases.2012;[Epub] CrossRef
Hepatitis B: Epidemiology and prevention in developing countries
Elisabetta Franco
World Journal of Hepatology.2012; 4(3): 74. CrossRef
Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients
Min-Sun Kwak, Eun-Ju Cho, Eun-Sun Jang, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Hyo-Suk Lee
Digestion.2011; 84(s1): 23. CrossRef
Comparison of cancer incidence between production and office workers at a shipyard in Korea: A retrospective cohort study from 1992 to 2005
Kyoung‐Sook Jeong, Yangho Kim, Moon‐Chan Kim, Cheol‐In Yoo
American Journal of Industrial Medicine.2011; 54(9): 719. CrossRef
The Management of Chronic Hepatitis B in Asian Americans
Myron J. Tong, Calvin Q. Pan, Hie-Won Hann, Kris V. Kowdley, Steven-Huy B. Han, Albert D. Min, Truong-Sinh Leduc
Digestive Diseases and Sciences.2011; 56(11): 3143. CrossRef
Trend in Viral Infectious Diseases in Children
Sung Hee Oh
Infection and Chemotherapy.2011; 43(6): 435. CrossRef
Infectious diseases in children and adolescents in the Republic of Korea; Past & recent status
Jong-Hyun Kim
Korean Journal of Pediatrics.2011; 54(12): 489. CrossRef
Anti-hepatitis B core antibody is not required for prevaccination screening in healthcare workers
Jaejun Shim, Kyung Yup Kim, Byung-Ho Kim, Heekyung Chun, Mi Suk Lee, Young Hwangbo, Jae Young Jang, Seok Ho Dong, Hyo Jong Kim, Young Woon Chang, Rin Chang
Vaccine.2011; 29(8): 1721. CrossRef
Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction
Ki Young Lee
Journal of Korean Diabetes.2011; 12(4): 190. CrossRef
Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy
J Yun, K H Kim, E S Kang, G-Y Gwak, M S Choi, J E Lee, S J Nam, J-H Yang, Y H Park, J S Ahn, Y-H Im
British Journal of Cancer.2011; 104(4): 559. CrossRef
Liver transplantation in South Korea
Soo Ryang Kim
Kanzo.2011; 52(2): 150. CrossRef
Shifting in Seroprevalence of HBsAg and Anti-HCV during Recent 10 Years in Adults Resident in Daegu and Gyeongbuk Province
Kyung In Lee, Kyung Sik Park, Hye Jin Seo, Tae Yul Kim, Eun Soo Kim, Byoung Kuk Jang, Woo Jin Chung, Kwang Bum Cho, Jae Seok Hwang
The Korean Journal of Gastroenterology.2011; 58(2): 82. CrossRef
Clinical Features of Retinopathy in Chronic Hepatitis B Patients With Treated With Peginterferon
Yong Dae Kwon, Ji Won Lim
Journal of the Korean Ophthalmological Society.2011; 52(1): 41. CrossRef
Clinical features of acute viral hepatitis B in Korea: a multi-center study
Hye Jin Choi, Soon Young Ko, Won Hyeok Choe, Yeon Seok Seo, Ji Hoon Kim, Kwan Soo Byun, Young Seok Kim, Seung Up Kim, Soon Koo Baik, Jae Youn Cheong, Tae Yeob Kim, Oh Sang Kwon, Jeong Han Kim, Chang Hong Lee, So Young Kwon
The Korean Journal of Hepatology.2011; 17(4): 307. CrossRef
New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B
Yoo-Kyung Cho, Byung-Cheol Song
The Korean Journal of Gastroenterology.2011; 57(3): 144. CrossRef
Quantitative Measurement of Serum Hepatitis B Surface Antigen Using an Immunoradiometric Assay in Chronic Hepatitis B
Hyun-Woo Kwon, Ho-Young Lee, Seog Gyun Kim, Won Kim, Yong Jin Jung, Keon Wook Kang, June-Key Chung, Myung Chul Lee, Dong Soo Lee
Nuclear Medicine and Molecular Imaging.2011; 45(1): 15. CrossRef
A Survey for Changed Control Policies of Hepatitis B in Republic of Korea
Ji Yoon Han, Tae Woong Jung, Dae Kyun Koh, Jong Hyun Kim
Korean Journal of Pediatric Infectious Diseases.2011; 18(2): 124. CrossRef
Prevalence of IgG anti-HAV in patients with chronic hepatitis B and in the general healthy population in Korea
Sang Ho Lee, Hyoung Su Kim, Kwon Oh Park, Jong Won Park, Seung Yeon Chun, Seung Jin Lim, Hyun Jung Cho, Sung Jun Kim, Hye Won Park, Han Kook Moon, Woon Geon Shin, Kyung Ho Kim, Myoung Kuk Jang, Jin Heon Lee, Hak Yang Kim
The Korean Journal of Hepatology.2010; 16(4): 362. CrossRef

10,184 View
105 Download
Crossref

Original Article

Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea: Byung Kook Kim, M.D., So Young Kwon, M.D., Chang Hong Lee, M.D., Won Hyeok Choe, M.D., Hong Mi Choi, M.S.1, Hye Won Koo, M.D.1; Korean J Hepatol 2009;15(1):25-41.
Published online March 31, 2009; DOI: https://doi.org/10.3350/kjhep.2009.15.1.25

Abstract
PDF

Backgrounds/Aims
The purpose of this study was to evaluate the cost-effectiveness of 1 year and up to 5 years of antiviral treatment for chronic hepatitis B (CHB). Methods: Two ten-health-state Markov models were developed for CHB patients. The proportion of patients remaining alive in each health state, and healthcare costs and quality-adjusted life years (QALYs) were determined during annual cycles of these Markov models. The total healthcare costs, life years, and QALYs over the 40-year time horizon of the model were calculated. The perspectives of the cost-effectiveness analysis were the Korean healthcare system and the healthcare needs of the CHB patient. Results: Short-course therapy with α-interferon or 1-year treatment with pegylated interferon α-2a, lamivudine (LMV), or adefovir (ADV) had limited impact on disease progression. In contrast, either LMV-ADV or ADV-LMV as rescue medication administered for 5 years resulted in a more sustained decrease in the rate of disease progression. The cost-effectiveness threshold in Korea was estimated to be approximately 25,000,000 South Korean won. LMV administered for 1 year is cost-effective in comparison with no treatment for both HBeAg-positive and HBeAg-negative CHB patients, but longer duration antiviral therapies administered for up to 5 years in CHB patients were found to be highly cost-effective by international standards. Conclusions: Antiviral treatment of CHB with LMV or ADV for up to 5 years using the alternative antiviral agent as rescue medication appears to be a cost-effective strategy for both HBeAg-positive and HBeAg-negative CHB patients in Korea. Economic evaluation of antiviral therapies should be studied further and updated, particularly for newer agents. (Korean J Hepatol 2008;15: 25-41)

Citations

Citations to this article as recorded by

Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B
Jeong Han Kim, So Young Kwon, Young Sok Lee, Joon Hyoek Lee, Yil–Seob Lee, Chang Hong Lee
Clinical Gastroenterology and Hepatology.2012; 10(3): 291. CrossRef
A tool for communication with decision-makers: limitations and utilization of studies on cost of illness
Kun-Sei Lee
The Korean Journal of Hepatology.2011; 17(4): 258. CrossRef
Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea
Kyoung Hee Lee, Se Jin Seo, Jayne Smith-Palmer, James L. Palmer, Jeremy White, William J. Valentine
Value in Health.2009; 12: S55. CrossRef

6,901 View
57 Download
Crossref

Review

Treatment of Chronic Hepatitis B ; Antiviral Therapy in Hepatitis B Carriers Undergoing Immunosuppressive Treatment or Cytotoxic Chemotherapy: Jung Hwan Yoon; Korean J Hepatol 2005;11(1):17-20.

3,259 View
12 Download

First

Page of 1

Last

Page Path

"Antiviral agent"

Article category

Keywords

Publication year

Article category

Keywords

Publication Year

Funded articles

"Antiviral agent"

Reply to Correspondence

Correspondences

Editorial

Correspondence

Reviews

Viral hepatitis

Viral hepatitis

Editorial

Viral hepatitis

Correspondence

Viral hepatitis

Original Articles

Viral hepatitis

Viral hepatitis

Letter to the Editor

Viral hepatitis

Original Article

Viral hepatitis

Review

Viral hepatitis

Editorial

Viral hepatitis

Original Articles

Viral hepatitis

Viral hepatitis

Editorial

Viral hepatitis

Review

Viral hepatitis

Original Articles

Viral hepatitis

Editorial

Viral hepatitis

Original Articles

Viral hepatitis

Viral hepatitis

Viral hepatitis

Viral hepatitis

Viral hepatitis

Original Article

ABOUT

BROWSE ARTICLES

FOR CONTRIBUTORS